#!/usr/bin/env python3
from reportlab.lib.pagesizes import A4
from reportlab.lib import colors
from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle
from reportlab.lib.units import cm
from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable, KeepTogether
from reportlab.lib.enums import TA_LEFT, TA_CENTER, TA_JUSTIFY

OUTPUT = "/home/daytona/workspace/surgery-exam/MS_Surgery_Exam_Q37_61.pdf"

doc = SimpleDocTemplate(
    OUTPUT,
    pagesize=A4,
    rightMargin=1.8*cm, leftMargin=1.8*cm,
    topMargin=2*cm, bottomMargin=2*cm
)

styles = getSampleStyleSheet()

# Custom styles
title_style = ParagraphStyle(
    'Title', parent=styles['Normal'],
    fontSize=16, fontName='Helvetica-Bold',
    alignment=TA_CENTER, spaceAfter=4, textColor=colors.HexColor('#1a237e')
)
subtitle_style = ParagraphStyle(
    'Subtitle', parent=styles['Normal'],
    fontSize=10, fontName='Helvetica-Oblique',
    alignment=TA_CENTER, spaceAfter=8, textColor=colors.HexColor('#37474f')
)
section_style = ParagraphStyle(
    'Section', parent=styles['Normal'],
    fontSize=13, fontName='Helvetica-Bold',
    spaceBefore=10, spaceAfter=4,
    textColor=colors.white,
    backColor=colors.HexColor('#1565c0'),
    leftIndent=-4, rightIndent=-4,
    borderPad=4
)
q_style = ParagraphStyle(
    'Question', parent=styles['Normal'],
    fontSize=11, fontName='Helvetica-Bold',
    spaceBefore=8, spaceAfter=2,
    textColor=colors.HexColor('#b71c1c'),
    backColor=colors.HexColor('#fff3e0'),
    leftIndent=0, borderPad=3
)
heading_style = ParagraphStyle(
    'Heading', parent=styles['Normal'],
    fontSize=10, fontName='Helvetica-Bold',
    spaceBefore=5, spaceAfter=1,
    textColor=colors.HexColor('#1565c0')
)
body_style = ParagraphStyle(
    'Body', parent=styles['Normal'],
    fontSize=9.5, fontName='Helvetica',
    spaceBefore=1, spaceAfter=1,
    leading=13, alignment=TA_JUSTIFY
)
bullet_style = ParagraphStyle(
    'Bullet', parent=styles['Normal'],
    fontSize=9.5, fontName='Helvetica',
    leftIndent=14, spaceBefore=1, spaceAfter=1,
    leading=13
)
note_style = ParagraphStyle(
    'Note', parent=styles['Normal'],
    fontSize=8.5, fontName='Helvetica-Oblique',
    textColor=colors.HexColor('#37474f'),
    spaceBefore=2, spaceAfter=2, leftIndent=6
)

def Q(num, text):
    return Paragraph(f"Q{num}. {text}", q_style)

def H(text):
    return Paragraph(text, heading_style)

def B(text):
    return Paragraph(text, body_style)

def BL(text):
    return Paragraph(f"• {text}", bullet_style)

def N(text):
    return Paragraph(f"[Source: Bailey & Love's 28th Ed | ~15 min answer]", note_style)

def SEC(text):
    return Paragraph(f"  {text}  ", section_style)

def HR():
    return HRFlowable(width="100%", thickness=0.5, color=colors.HexColor('#90caf9'), spaceAfter=4, spaceBefore=4)

story = []

# COVER
story.append(Spacer(1, 1.5*cm))
story.append(Paragraph("MS GENERAL SURGERY", title_style))
story.append(Paragraph("EXAM-READY STRUCTURED ANSWERS", title_style))
story.append(Spacer(1, 0.3*cm))
story.append(Paragraph("Questions 37 – 61 | Bailey & Love's Short Practice of Surgery, 28th Edition", subtitle_style))
story.append(Paragraph("Each answer: ~15 minutes | Key scoring points included", subtitle_style))
story.append(Spacer(1, 0.5*cm))
story.append(HR())
story.append(Spacer(1, 0.3*cm))

# ============================================================
# SECTION: SHOCK & SEPSIS
# ============================================================
story.append(SEC("SECTION A: SHOCK & SEPSIS  (Q37–41)"))
story.append(Spacer(1, 0.2*cm))

# ---- Q37 ----
story.append(Q(37, "Criteria of SIRS (2013, 2021)"))
story.append(H("Definition"))
story.append(B("SIRS = Systemic Inflammatory Response Syndrome. A non-specific clinical response to a severe insult (infectious or non-infectious)."))
story.append(H("Diagnostic Criteria (any 2 of 4):"))
data = [
    ["Parameter", "Abnormal Value"],
    ["Temperature", "> 38°C  OR  < 36°C"],
    ["Heart Rate", "> 90 bpm"],
    ["Respiratory Rate", "> 20 breaths/min  OR  PaCO₂ < 4.3 kPa (32 mmHg)"],
    ["WBC Count", "> 12,000/mm³  OR  < 4,000/mm³  OR  > 10% immature (band) forms"],
]
t = Table(data, colWidths=[5*cm, 9*cm])
t.setStyle(TableStyle([
    ('BACKGROUND', (0,0), (-1,0), colors.HexColor('#1565c0')),
    ('TEXTCOLOR', (0,0), (-1,0), colors.white),
    ('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'),
    ('FONTSIZE', (0,0), (-1,-1), 9),
    ('ROWBACKGROUNDS', (0,1), (-1,-1), [colors.HexColor('#e3f2fd'), colors.white]),
    ('GRID', (0,0), (-1,-1), 0.4, colors.HexColor('#90caf9')),
    ('VALIGN', (0,0), (-1,-1), 'MIDDLE'),
    ('TOPPADDING', (0,0), (-1,-1), 3),
    ('BOTTOMPADDING', (0,0), (-1,-1), 3),
]))
story.append(t)
story.append(H("Sepsis-3 Definitions (2016 – tested as 2021 update):"))
story.append(BL("Sepsis = life-threatening organ dysfunction caused by dysregulated host response to infection"))
story.append(BL("Organ dysfunction = SOFA score increase ≥ 2 points"))
story.append(BL("Septic shock = sepsis + vasopressor requirement + serum lactate > 2 mmol/L despite adequate fluid resuscitation"))
story.append(BL("qSOFA (bedside): RR ≥ 22, altered mentation, systolic BP ≤ 100 – 2 of 3 = suspect sepsis"))
story.append(H("Progression: SIRS → Sepsis → Severe Sepsis → Septic Shock → MODS"))
story.append(N("Bailey & Love Ch. 2 | Sepsis-3 (Singer et al., JAMA 2016)"))
story.append(HR())

# ---- Q38 ----
story.append(Q(38, "Pathogenesis of Sepsis-Induced Hypotension (2014)"))
story.append(H("Mechanism Overview:"))
story.append(B("Infection → Pattern Recognition Receptors (TLRs) → NF-κB activation → Cytokine storm → Cardiovascular dysfunction"))
story.append(H("Key Steps:"))
story.append(BL("1. LPS/PAMP activates macrophages → releases TNF-α, IL-1β, IL-6, IL-8"))
story.append(BL("2. iNOS upregulation → excess Nitric Oxide (NO) → profound vasodilation → ↓ SVR"))
story.append(BL("3. Endothelial injury → capillary leak → intravascular hypovolaemia"))
story.append(BL("4. Myocardial depression – TNF-α + IL-1β suppress myocardial contractility"))
story.append(BL("5. Relative adrenal insufficiency in prolonged sepsis"))
story.append(BL("6. Mitochondrial dysfunction → cellular dysoxia even with adequate O₂ delivery"))
story.append(H("Haemodynamic Profile of Septic Shock:"))
data2 = [
    ["Parameter", "Early (Warm)","Late (Cold)"],
    ["Cardiac Output", "↑ (High)","↓ (Low)"],
    ["SVR","↓ (Low)","↓↓ (Very Low)"],
    ["PCWP","Low","Low"],
    ["Mixed venous O₂","High","Low"],
]
t2 = Table(data2, colWidths=[5*cm, 4.5*cm, 4.5*cm])
t2.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#1565c0')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),9),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#e3f2fd'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#90caf9')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t2)
story.append(H("Management of Septic Shock (Surviving Sepsis Campaign 'Hour-1 Bundle'):"))
story.append(BL("Measure lactate (re-measure if > 2 mmol/L)"))
story.append(BL("Blood cultures × 2 (before antibiotics)"))
story.append(BL("Broad-spectrum antibiotics within 1 hour"))
story.append(BL("30 mL/kg crystalloid (Hartmann's/NS) for hypotension or lactate ≥ 4"))
story.append(BL("Vasopressor if MAP < 65 mmHg → Noradrenaline (1st line), Vasopressin (add-on), Dobutamine (if low CO)"))
story.append(N("Bailey & Love Ch. 2 | Surviving Sepsis Campaign 2021"))
story.append(HR())

# ---- Q39 ----
story.append(Q(39, "Distributive Shock (2014)"))
story.append(H("Definition:"))
story.append(B("Maldistribution of blood flow due to pathological vasodilation → high CO + low SVR → tissue hypoperfusion despite adequate circulating volume."))
story.append(H("Types:"))
story.append(BL("Septic shock (most common) – endotoxin-mediated NO release"))
story.append(BL("Anaphylactic shock – IgE-mediated histamine/leukotriene release → vasodilation + bronchospasm"))
story.append(BL("Neurogenic shock – spinal cord injury (T6 or above) → loss of sympathetic tone → vasodilation + bradycardia"))
story.append(BL("Toxic shock syndrome – superantigen-mediated massive cytokine release"))
story.append(H("Classic Haemodynamic Profile:"))
story.append(BL("↑ Cardiac output | ↓ SVR | ↓ PCWP | ↑ Mixed venous O₂ saturation | Warm extremities"))
story.append(H("Management:"))
story.append(BL("Septic: Antibiotics + IV fluids + Noradrenaline"))
story.append(BL("Anaphylactic: IM Adrenaline 0.5 mg (1:1000) + IV fluids + steroids + antihistamines + salbutamol"))
story.append(BL("Neurogenic: IV fluids + vasopressors (phenylephrine) + atropine for bradycardia"))
story.append(N("Bailey & Love Ch. 2, Table 2.1"))
story.append(HR())

# ---- Q40 ----
story.append(Q(40, "Biomarkers of Sepsis (2023)"))
story.append(H("Ideal Biomarker Properties: Early, sensitive, specific, cheap, measurable at bedside"))
data3 = [
    ["Biomarker","Normal","Sepsis Value","Role"],
    ["Procalcitonin (PCT)","< 0.1 ng/mL","> 2 ng/mL","Diagnosis, de-escalation of Abx"],
    ["C-Reactive Protein","< 10 mg/L","> 100 mg/L","Diagnosis & monitoring"],
    ["Lactate","< 2 mmol/L","> 2 mmol/L","Tissue hypoxia, prognosis"],
    ["IL-6","Low","> 1000 pg/mL","Early sepsis, cytokine storm"],
    ["Presepsin (sCD14-ST)","< 300 pg/mL","Elevated","Early macrophage activation"],
    ["Soluble Triggering Receptor\n(sTREM-1)","Low","Elevated","Amplifies inflammatory signal"],
    ["WBC / CRP ratio","—","Elevated","Simple bedside marker"],
    ["Blood cultures","Sterile","Growth","Definitive – gold standard"],
]
t3 = Table(data3, colWidths=[4*cm, 2.8*cm, 2.8*cm, 4.4*cm])
t3.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#1565c0')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),8),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#e3f2fd'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#90caf9')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t3)
story.append(H("Procalcitonin – Most Clinically Useful:"))
story.append(BL("Rises 2-4 h after bacterial infection (faster than CRP)"))
story.append(BL("PCT-guided therapy reduces antibiotic duration by ~3 days"))
story.append(BL("Does NOT rise significantly in viral infections or autoimmune disease"))
story.append(BL("PCT < 0.5 ng/mL = consider stopping antibiotics"))
story.append(N("Bailey & Love Ch. 2 | Sepsis-3 2016 | ADRENAL trial 2018"))
story.append(HR())

# ---- Q41 ----
story.append(Q(41, "Pathophysiology and Management of Haemorrhagic Shock"))
story.append(H("ATLS Classification of Haemorrhage:"))
data4 = [
    ["Class","Blood Loss (mL)","% Blood Vol","HR","BP","RR","Urine (mL/h)","CNS"],
    ["I","< 750","< 15%","< 100","Normal","14-20","> 30","Normal"],
    ["II","750-1500","15-30%","100-120","Normal","20-30","20-30","Anxious"],
    ["III","1500-2000","30-40%","120-140","↓","30-40","5-20","Confused"],
    ["IV","> 2000","> 40%","> 140","↓↓","35+","< 5","Lethargic"],
]
t4 = Table(data4, colWidths=[1.2*cm, 2.3*cm, 2*cm, 1.4*cm, 1.4*cm, 1.4*cm, 2.2*cm, 2*cm])
t4.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#b71c1c')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,-1),'Helvetica-Bold'),
    ('FONTNAME',(0,1),(-1,-1),'Helvetica'),
    ('FONTSIZE',(0,0),(-1,-1),7.5),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#ffebee'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#ef9a9a')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t4)
story.append(H("Pathophysiology:"))
story.append(BL("↓ Circulating volume → ↓ Preload → ↓ CO → ↓ MAP"))
story.append(BL("Compensatory: ↑ HR, ↑ SVR (vasoconstriction), ADH, RAAS activation"))
story.append(BL("Prolonged: organ ischaemia → acidosis → Trauma-Induced Coagulopathy (TIC)"))
story.append(BL("TIC = Lethal Triad: Hypothermia + Acidosis + Coagulopathy"))
story.append(H("Management – Damage Control Resuscitation:"))
story.append(BL("Stop the bleeding (surgical/interventional) – PRIMARY goal"))
story.append(BL("Permissive hypotension: target MAP 50-65 mmHg until surgical control (avoid in TBI)"))
story.append(BL("Haemostatic resuscitation: pRBC : FFP : Platelets = 1:1:1"))
story.append(BL("Tranexamic acid 1g IV within 3 hours of injury (CRASH-2 trial)"))
story.append(BL("Warm fluids + warming blanket (combat hypothermia)"))
story.append(BL("Calcium replacement (ionised Ca²⁺ falls with massive transfusion)"))
story.append(BL("Avoid dilutional coagulopathy – limit crystalloids"))
story.append(H("Endpoints of Resuscitation:"))
story.append(BL("Lactate clearance (< 2 mmol/L) | Base excess > -6 | Urine output > 0.5 mL/kg/h | Normal coagulation"))
story.append(N("Bailey & Love Ch. 2 | CRASH-2 Trial | ATLS 10th Ed"))
story.append(HR())

# ============================================================
# SECTION: BLOOD COAGULATION
# ============================================================
story.append(SEC("SECTION B: BLOOD COAGULATION  (Q42–44)"))
story.append(Spacer(1, 0.2*cm))

# ---- Q42 ----
story.append(Q(42, "Physiology of Blood Coagulation and Its Importance in Surgery (2024)"))
story.append(H("Primary Haemostasis:"))
story.append(BL("Injury → vascular spasm → platelet adhesion (via vWF to collagen – GPIb receptor)"))
story.append(BL("Platelet activation: shape change, release of ADP, TXA₂, serotonin"))
story.append(BL("Platelet aggregation: GPIIb/IIIa receptor binds fibrinogen → platelet plug"))
story.append(H("Secondary Haemostasis – Coagulation Cascade:"))
story.append(B("Cell-based model (modern):"))
story.append(BL("Initiation: TF (tissue factor) + FVIIa → FXa + FIXa → small thrombin burst"))
story.append(BL("Amplification: thrombin activates platelets, FV, FVIII, FXI"))
story.append(BL("Propagation: FIXa/FVIIIa complex (tenase) + FXa/FVa (prothrombinase) → large thrombin burst → fibrin clot"))
story.append(H("Classic Cascade:"))
data5 = [
    ["Pathway","Factors","Test"],
    ["Intrinsic (contact)","XII → XI → IX → X","APTT"],
    ["Extrinsic (TF)","VII → X","PT/INR"],
    ["Common","X → Thrombin → Fibrin","Both"],
]
t5 = Table(data5, colWidths=[4.5*cm, 6.5*cm, 3*cm])
t5.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#1565c0')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),9),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#e3f2fd'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#90caf9')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t5)
story.append(H("Fibrinolysis:"))
story.append(BL("tPA activates plasminogen → plasmin → cleaves fibrin → FDPs/D-dimers"))
story.append(BL("Regulated by PAI-1 (inhibits tPA) and α₂-antiplasmin"))
story.append(H("Surgical Importance:"))
story.append(BL("Pre-op: identify coagulopathy (PT, APTT, platelets, bleeding time)"))
story.append(BL("Intra-op: haemostasis techniques – diathermy, ligature, topical agents (surgicel, gelfoam)"))
story.append(BL("Post-op: DVT prophylaxis (LMWH, compression stockings) vs. bleeding risk"))
story.append(BL("Drug effects: Warfarin (blocks Vit K factors II,VII,IX,X) | Aspirin (irreversible COX-1 inhibition) | NOACs"))
story.append(N("Bailey & Love Ch. 4 & Ch. 2"))
story.append(HR())

# ---- Q43 ----
story.append(Q(43, "Coagulation Disorders and Their Management"))
story.append(H("Classification:"))
story.append(BL("A. Inherited disorders"))
story.append(BL("B. Acquired disorders"))
data6 = [
    ["Disorder","Defect","PT","APTT","Platelet","Treatment"],
    ["Haemophilia A","Factor VIII deficiency","N","↑","N","Factor VIII concentrate / DDAVP"],
    ["Haemophilia B","Factor IX deficiency","N","↑","N","Factor IX concentrate"],
    ["vWD","vWF deficiency/dysfunction","N","↑/N","N/↓","DDAVP / FFP / cryoprecipitate"],
    ["DIC","Consumption of all factors","↑","↑","↓","Treat cause, FFP, cryo, platelets"],
    ["Liver disease","Reduced factor synthesis","↑","↑","↓","Vit K, FFP, platelets"],
    ["Warfarin OD","Vit K factors ↓","↑","N/↑","N","Vit K, PCC (4-factor)"],
    ["Thrombocytopenia","Low platelets","N","N","< 50","Platelet transfusion if < 10-50"],
    ["ITP","Anti-platelet antibodies","N","N","↓","Steroids, IVIG, splenectomy"],
]
t6 = Table(data6, colWidths=[3*cm, 3.5*cm, 1.1*cm, 1.3*cm, 1.4*cm, 3.7*cm])
t6.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#1565c0')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),7.5),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#e3f2fd'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#90caf9')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t6)
story.append(H("DIC – Disseminated Intravascular Coagulation:"))
story.append(BL("Triggers: sepsis, trauma, obstetric emergencies, malignancy, transfusion reactions"))
story.append(BL("Pathophysiology: widespread TF exposure → systemic thrombin generation → fibrin thrombi + consumption of clotting factors + secondary fibrinolysis"))
story.append(BL("Lab: ↑PT, ↑APTT, ↓Fibrinogen, ↓Platelets, ↑D-dimer, ↑FDPs"))
story.append(BL("Management: TREAT THE CAUSE + supportive (FFP, cryoprecipitate, platelets, pRBCs)"))
story.append(N("Bailey & Love Ch. 4"))
story.append(HR())

# ---- Q44 ----
story.append(Q(44, "Coagulopathy in Trauma Patients (2021)"))
story.append(H("Acute Traumatic Coagulopathy (ATC):"))
story.append(BL("Occurs within minutes of injury in up to 25% of trauma patients"))
story.append(BL("4-fold increase in mortality"))
story.append(BL("Driven by: shock + tissue injury → protein C activation → systemic anticoagulation + hyperfibrinolysis"))
story.append(H("Lethal Triad / Trauma-Induced Coagulopathy (TIC):"))
data7 = [
    ["Component","Effect on Coagulation","Threshold"],
    ["Hypothermia (< 34°C)","Impairs enzymatic coagulation reactions","< 34°C critical"],
    ["Acidosis (pH < 7.2)","Inhibits thrombin generation, impairs platelet function","pH < 7.2"],
    ["Haemodilution","Dilutes clotting factors & platelets","After 10+ unit pRBC"],
]
t7 = Table(data7, colWidths=[4.5*cm, 6*cm, 3.5*cm])
t7.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#b71c1c')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),8.5),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#ffebee'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#ef9a9a')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t7)
story.append(H("Assessment:"))
story.append(BL("ROTEM/TEG (thromboelastography) – bedside viscoelastic testing – gold standard for guiding product replacement"))
story.append(BL("Conventional: PT, APTT, fibrinogen, platelet count, D-dimer"))
story.append(H("Damage Control Resuscitation (DCR):"))
story.append(BL("1:1:1 ratio pRBC:FFP:Platelets (PROPPR trial – improved haemostasis)"))
story.append(BL("Tranexamic acid (TXA) 1g IV within 3 hours → reduces hyperfibrinolysis (CRASH-2)"))
story.append(BL("Fibrinogen concentrate / cryoprecipitate if fibrinogen < 1.5 g/L"))
story.append(BL("Calcium (CaCl₂ or gluconate) – citrate in blood products chelates Ca²⁺"))
story.append(BL("Damage Control Surgery – temporary haemostasis, pack, close, return for definitive repair"))
story.append(BL("Avoid crystalloid excess – worsens acidosis and dilutional coagulopathy"))
story.append(N("Bailey & Love Ch. 2 | PROPPR Trial | CRASH-2 Trial"))
story.append(HR())

# ============================================================
# SECTION: BLOOD TRANSFUSION
# ============================================================
story.append(SEC("SECTION C: BLOOD TRANSFUSION  (Q45–54)"))
story.append(Spacer(1, 0.2*cm))

# ---- Q45 ----
story.append(Q(45, "Blood Component Separation and Their Role in Surgery (2016, 2017)"))
story.append(H("Whole Blood → Component Separation (by centrifugation):"))
data8 = [
    ["Component","Contents","Storage","Indication in Surgery"],
    ["Packed RBCs (pRBC)","RBCs, minimal plasma","4°C, 35-42 days","Anaemia, haemorrhage (Hb<7 or <8 in cardiac)"],
    ["Fresh Frozen Plasma (FFP)","All clotting factors","−30°C, 1 year","DIC, massive transfusion, warfarin reversal"],
    ["Platelet Concentrate","Platelets in plasma","22°C (agitated), 5-7 days","Plt <50k pre-op, <10k prophylactic"],
    ["Cryoprecipitate","FVIII, vWF, fibrinogen, FXIII","−30°C, 1 year","Haemophilia A, vWD, DIC, TIC"],
    ["Albumin","Colloid protein","Room temp","Hypoalbuminaemia, SBP treatment"],
    ["Granulocytes","WBCs","24h (NO irradiation)","Severe neutropenic sepsis (rare)"],
    ["Factor Concentrates","Specific factors","Varied","Haemophilia (VIIIc, IXc), PCC"],
]
t8 = Table(data8, colWidths=[3.5*cm, 4*cm, 2.5*cm, 4*cm])
t8.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#1565c0')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),7.5),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#e3f2fd'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#90caf9')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t8)
story.append(H("Leucodepletion (Universal in UK since 1999):"))
story.append(BL("Removes WBCs from all blood products"))
story.append(BL("Prevents: febrile non-haemolytic reactions, CMV transmission, variant CJD, HLA alloimmunisation"))
story.append(H("Irradiation:"))
story.append(BL("Prevents transfusion-associated GvHD (TA-GvHD) in immunocompromised patients"))
story.append(N("Bailey & Love Ch. 4"))
story.append(HR())

# ---- Q46 ----
story.append(Q(46, "Blood Substitutes and Changes in Stored Blood (2011, 2023)"))
story.append(H("Changes in Stored Blood (Storage Lesion):"))
data9 = [
    ["Change","Effect"],
    ["↓ 2,3-DPG","Left shift O₂ curve → impaired O₂ release to tissues"],
    ["↑ K⁺ (hyperkalaemia)","RBC lysis releases intracellular K⁺"],
    ["↓ pH (acidosis)","CO₂ accumulation, lactate buildup"],
    ["↑ microaggregates","Microthrombi formation"],
    ["↑ Free haemoglobin","Renal tubular toxicity"],
    ["↓ Factor V, VIII","Labile factors degrade (retained in FFP)"],
    ["↑ Citrate","Chelates Ca²⁺ → hypocalcaemia in massive transfusion"],
    ["Hypothermia","Cold blood → cardiac arrhythmias"],
]
t9 = Table(data9, colWidths=[5*cm, 9*cm])
t9.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#1565c0')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),8.5),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#e3f2fd'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#90caf9')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t9)
story.append(H("Blood Substitutes (Haemoglobin-Based Oxygen Carriers / PFCs):"))
story.append(BL("HBOCs (e.g. HBOC-201/Hemopure): polymerised Hb → carries O₂, no cross-matching"))
story.append(BL("Perfluorocarbons (PFCs): dissolve O₂, require high FiO₂"))
story.append(BL("Limitations: vasoconstriction, oxidative stress, short half-life, not yet in routine use"))
story.append(BL("Future: recombinant Hb, nano-RBCs, universal donor RBCs"))
story.append(N("Bailey & Love Ch. 4"))
story.append(HR())

# ---- Q47 ----
story.append(Q(47, "How Will You Assess the Amount of Blood Loss in a Surgical Patient? (2021)"))
story.append(H("A. Clinical Assessment:"))
story.append(BL("History: site of injury/surgery, drain output, swab weight"))
story.append(BL("Vital signs: HR, BP, RR, pulse pressure, capillary refill > 2 sec, urine output"))
story.append(BL("ATLS Classes I-IV (see Q41)"))
story.append(H("B. Investigations:"))
story.append(BL("FBC: Hb (note: early haemorrhage Hb may be normal due to haemoconcentration)"))
story.append(BL("ABG: Lactate, Base deficit (BD > -6 = significant shock)"))
story.append(BL("Coagulation profile: PT, APTT, fibrinogen"))
story.append(BL("Cross-match / Blood group & save"))
story.append(H("C. Quantitative Methods:"))
story.append(BL("Swab weighing (1 g = 1 mL blood)"))
story.append(BL("Suction canister measurement"))
story.append(BL("Estimated blood loss (EBL) = EBV × (initial Hct − final Hct) / initial Hct"))
story.append(BL("EBV: 70 mL/kg adult, 80-85 mL/kg child"))
story.append(H("D. Shock Index:"))
story.append(BL("SI = HR / Systolic BP | Normal 0.5-0.7 | > 1.0 = significant haemorrhage"))
story.append(N("Bailey & Love Ch. 2 & Ch. 4"))
story.append(HR())

# ---- Q48 ----
story.append(Q(48, "Classification, Indications and Complications of Allogeneic Blood Transfusion (2025)"))
story.append(H("Definition:"))
story.append(B("Allogeneic = transfusion of blood from another individual (donor to recipient)."))
story.append(H("Indications:"))
story.append(BL("Symptomatic anaemia unresponsive to medical treatment"))
story.append(BL("Acute haemorrhage: Class III/IV shock, Hb < 7 g/dL (< 8 in cardiac disease)"))
story.append(BL("Platelets < 10 × 10⁹/L (prophylactic) or < 50 × 10⁹/L (pre-operative)"))
story.append(BL("Coagulopathy: FFP for PT/APTT > 1.5× normal; Cryoprecipitate if fibrinogen < 1.5 g/L"))
story.append(H("Pre-Transfusion Checks (BCSH guidelines – never skip):"))
story.append(BL("ABO/Rh typing | Crossmatch | Bedside ID check (2 identifiers) | Consent"))
story.append(H("Complications – SHOT Classification:"))
data10 = [
    ["Type","Reaction","Mechanism","Management"],
    ["Acute (<24h)","Acute haemolytic","ABO incompatibility","STOP transfusion, fluids, frusemide, FFP"],
    ["Acute (<24h)","FNHTR","WBC antibodies","Paracetamol, slow rate, leucodepletion"],
    ["Acute (<24h)","Anaphylaxis","IgA deficiency","Adrenaline, steroids, antihistamines"],
    ["Acute (<24h)","TACO","Volume overload","Diuretics, oxygen, upright position"],
    ["Acute (<24h)","TRALI","Anti-HLA/HNA Ab","Supportive, stop, O₂, ICU"],
    ["Acute (<24h)","Septic shock","Bacterial contamination","Blood culture, IV antibiotics"],
    ["Delayed (>24h)","Delayed haemolytic","Amnestic Ab response","Monitor renal function"],
    ["Delayed","TA-GvHD","Donor T-cells","Irradiation (PREVENTION only)"],
    ["Delayed","Iron overload","Repeated transfusion","Desferrioxamine chelation"],
    ["Delayed","Infection","HIV, Hep B/C, CMV","Screening, leucodepletion"],
]
t10 = Table(data10, colWidths=[2*cm, 2.8*cm, 4*cm, 5.2*cm])
t10.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#b71c1c')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),7),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#ffebee'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#ef9a9a')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t10)
story.append(N("Bailey & Love Ch. 4 | SHOT Annual Report"))
story.append(HR())

# ---- Q49 ----
story.append(Q(49, "Autologous Blood Transfusion – Types and Advantages (2021, 2022)"))
story.append(H("Definition:"))
story.append(B("Collection and re-infusion of patient's own blood → eliminates allogeneic risks."))
story.append(H("Types:"))
story.append(BL("1. Pre-operative autologous donation (PAD): collect 2-4 weeks before elective surgery, stored refrigerated. Risk: anaemia pre-op."))
story.append(BL("2. Acute normovolaemic haemodilution (ANH): remove blood at start of surgery, replace with crystalloid, re-infuse at end."))
story.append(BL("3. Intra-operative cell salvage (ICS): suction blood from surgical field → wash → re-infuse. Used in cardiac, vascular, orthopaedic surgery."))
story.append(BL("4. Post-operative wound drainage salvage: collect drain blood, filter, re-infuse within 6 hours."))
story.append(H("Advantages:"))
story.append(BL("Eliminates risk of alloimmunisation, infectious disease transmission, TRALI, TA-GvHD"))
story.append(BL("Reduces allogeneic transfusion demand"))
story.append(BL("Fresh, 2,3-DPG replete blood (cell salvage)"))
story.append(BL("Acceptable to certain religious groups (e.g. Jehovah's Witnesses may accept cell salvage)"))
story.append(H("Contraindications for Cell Salvage:"))
story.append(BL("Malignant field (relative) | Bowel contamination | Amniotic fluid (relative) | Topical haemostatics (relative)"))
story.append(N("Bailey & Love Ch. 4"))
story.append(HR())

# ---- Q50 ----
story.append(Q(50, "Massive Blood Transfusion – Definition, Complications, Management (2022)"))
story.append(H("Definition:"))
story.append(BL("Transfusion of ≥ 10 units pRBC in 24 hours  OR"))
story.append(BL("Replacement of entire blood volume within 24 hours  OR"))
story.append(BL("Transfusion of > 4 units pRBC in 1 hour with anticipated continued need"))
story.append(H("Complications:"))
story.append(BL("Dilutional coagulopathy (↓ clotting factors, ↓ platelets)"))
story.append(BL("Hypocalcaemia (citrate chelates Ca²⁺) → myocardial depression, coagulopathy"))
story.append(BL("Hyperkalaemia (K⁺ leaks from stored RBCs) → arrhythmias"))
story.append(BL("Hypothermia → enzyme inhibition, cardiac arrhythmias"))
story.append(BL("Metabolic acidosis (lactate + citrate from stored blood)"))
story.append(BL("TACO – Transfusion-Associated Circulatory Overload"))
story.append(BL("TRALI – acute lung injury within 6h"))
story.append(BL("Haemolytic reactions (ABO error under emergency pressure)"))
story.append(H("Management – Massive Haemorrhage Protocol (MHP):"))
story.append(BL("ACTIVATE MHP: Alert haematology, blood bank, consultant surgeon + anaesthetist"))
story.append(BL("Empiric 1:1:1 pRBC:FFP:Platelets (do NOT wait for labs)"))
story.append(BL("Tranexamic acid 1g IV stat + 1g over 8h"))
story.append(BL("Calcium gluconate 10 mL 10% IV after every 4 units pRBC"))
story.append(BL("Warm blood using in-line warmer (target >37°C)"))
story.append(BL("Monitor with ROTEM/TEG and guide product use"))
story.append(BL("Fibrinogen: cryoprecipitate if < 1.5 g/L (target > 2 g/L)"))
story.append(BL("Recombinant FVIIa (NovoSeven) as last resort"))
story.append(N("Bailey & Love Ch. 4 | PROPPR Trial | CRASH-2"))
story.append(HR())

# ---- Q51 ----
story.append(Q(51, "Applications of Platelet-Rich Plasma (PRP) in Surgical Practice (2021)"))
story.append(H("Preparation:"))
story.append(BL("Autologous blood centrifuged → platelet concentration 5-10× baseline"))
story.append(BL("Platelet conc > 1 million/µL in PRP (normal: 150,000-400,000/µL)"))
story.append(H("Growth Factors in PRP:"))
story.append(BL("PDGF, TGF-β, VEGF, EGF, IGF → stimulate healing, angiogenesis, collagen synthesis"))
story.append(H("Surgical Applications:"))
story.append(BL("Orthopaedics: cartilage repair, tendinopathy, bone graft enhancement"))
story.append(BL("Plastic surgery: wound healing, skin graft take, scar management"))
story.append(BL("Maxillofacial: dental implants, jaw reconstruction, sinus lifts"))
story.append(BL("Vascular surgery: anastomosis healing"))
story.append(BL("Cardiothoracic: sternal wound healing post-sternotomy"))
story.append(BL("Colorectal: perianal fistula treatment"))
story.append(H("Evidence:"))
story.append(BL("Still evolving – good evidence for knee osteoarthritis, chronic wounds"))
story.append(BL("Low-quality evidence for many other applications (level IIb-III)"))
story.append(N("Bailey & Love Ch. 4"))
story.append(HR())

# ---- Q52 ----
story.append(Q(52, "Complications of Blood Transfusion"))
story.append(H("See Q48 for detailed table. Additional points:"))
story.append(H("Mnemonic – INCH (Immune/Infective/Non-immune/Chemical):"))
story.append(BL("Immune: haemolytic (ABO/minor Ag), febrile non-haemolytic, urticarial, anaphylaxis, TRALI, TA-GvHD, alloimmunisation"))
story.append(BL("Infective: HIV (1:2.5M), Hep C (1:1.5M), Hep B (1:220,000), CMV, malaria, vCJD, bacterial (Yersinia in platelets)"))
story.append(BL("Non-immune/Physical: TACO, air embolism, hypothermia, haemorrhagic dilution"))
story.append(BL("Chemical/Metabolic: hyperkalaemia, hypocalcaemia, iron overload (> 20 units → haemosiderosis)"))
story.append(H("Most Dangerous:"))
story.append(BL("ACUTE HAEMOLYTIC REACTION (ABO mismatch) → intravascular haemolysis → DIC → ARF → death"))
story.append(BL("First sign: 'feeling of impending doom' / loin pain / haemoglobinuria"))
story.append(BL("Action: STOP transfusion immediately, maintain IV access, send unit + patient sample to lab"))
story.append(N("Bailey & Love Ch. 4"))
story.append(HR())

# ---- Q53 ----
story.append(Q(53, "Blood Products, Plasma Expanders for Patient with Shock after Polytrauma; Complications of Blood Transfusion"))
story.append(H("Blood Products (see Q45 & Q48)"))
story.append(H("Plasma Expanders – Crystalloids:"))
story.append(BL("Normal saline (0.9%): iso-osmolar, risk of hyperchloraemic acidosis with large volumes"))
story.append(BL("Hartmann's/Ringer's lactate: balanced, preferred in trauma resuscitation"))
story.append(BL("Dextrose: NOT for resuscitation (hypotonic, stays intracellular, worsens cerebral oedema)"))
story.append(H("Plasma Expanders – Colloids:"))
story.append(BL("Human albumin solution (HAS 4-5%): expensive, used in liver failure/SBP"))
story.append(BL("Gelatin (Gelofusine, Haemaccel): half-life 2-3h, risk of anaphylaxis, coagulopathy"))
story.append(BL("Dextran: improves rheology, antithrombotic – largely obsolete"))
story.append(BL("Hydroxyethyl starch (HES/Voluven): AVOID in sepsis and renal impairment (CHEST trial – increased mortality + AKI)"))
story.append(H("Principles for Polytrauma Resuscitation:"))
story.append(BL("Permissive hypotension (MAP 50-65) until surgical haemostasis"))
story.append(BL("Haemostatic resuscitation: 1:1:1 (pRBC:FFP:Plt) – early FFP"))
story.append(BL("Minimal crystalloid to avoid dilutional coagulopathy"))
story.append(BL("TXA early (CRASH-2) | Calcium replacement | Warm fluids"))
story.append(N("Bailey & Love Ch. 2 & Ch. 4 | ATLS 10th Ed"))
story.append(HR())

# ---- Q54 ----
story.append(Q(54, "TRALI – Definition, Mechanism and Management (2021)"))
story.append(H("Definition:"))
story.append(B("Transfusion-Related Acute Lung Injury = new acute lung injury within 6 hours of transfusion, with PaO₂/FiO₂ < 300 mmHg (or SpO₂ < 90% on room air), bilateral pulmonary infiltrates on CXR, NO evidence of pre-existing ALI or circulatory overload (TACO)."))
story.append(H("Incidence:"))
story.append(BL("1:5,000 – 1:190,000 transfusions | 3rd most common cause of transfusion-related death"))
story.append(H("Mechanism:"))
story.append(BL("Two-hit model:"))
story.append(BL("Hit 1: patient's pre-existing condition primes pulmonary neutrophils (e.g. surgery, sepsis, trauma)"))
story.append(BL("Hit 2: donor antibodies (anti-HLA class I/II or anti-HNA) in transfused product activate primed neutrophils"))
story.append(BL("Neutrophil activation → reactive oxygen species + proteases → endothelial damage → capillary leak → non-cardiogenic pulmonary oedema"))
story.append(BL("Most commonly implicated: FFP and platelets from multiparous female donors (HLA antibodies from pregnancy)"))
story.append(H("Differentiate TRALI vs TACO:"))
data11 = [
    ["Feature","TRALI","TACO"],
    ["Mechanism","Non-cardiogenic (Ab-mediated)","Cardiogenic (volume overload)"],
    ["JVP/CVP","Normal/↓","Elevated"],
    ["Response to diuretics","No","Yes"],
    ["BNP/pro-BNP","Normal","Elevated"],
    ["CXR","Bilateral infiltrates (no effusion)","Bilateral infiltrates + effusion"],
    ["Management","O₂, ventilatory support, ICU","Diuresis, O₂, CPAP"],
]
t11 = Table(data11, colWidths=[3*cm, 5.5*cm, 5.5*cm])
t11.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#1565c0')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),8.5),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#e3f2fd'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#90caf9')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t11)
story.append(H("Management of TRALI:"))
story.append(BL("STOP transfusion immediately"))
story.append(BL("High-flow O₂; escalate to CPAP/BiPAP or mechanical ventilation if needed"))
story.append(BL("Lung-protective ventilation (low tidal volume 6 mL/kg, PEEP)"))
story.append(BL("NO diuretics (not volume overload)"))
story.append(BL("Report to blood bank and haemovigilance system (SHOT in UK)"))
story.append(BL("Donor look-back investigation and testing for HLA/HNA antibodies"))
story.append(BL("Prevention: use male-only or nulliparous donors for plasma-rich products"))
story.append(N("Bailey & Love Ch. 4 | SHOT Report 2023"))
story.append(HR())

# ============================================================
# SECTION: ANAESTHESIA & CRITICAL CARE
# ============================================================
story.append(SEC("SECTION D: ANAESTHESIA & CRITICAL CARE  (Q55–61)"))
story.append(Spacer(1, 0.2*cm))

# ---- Q55 ----
story.append(Q(55, "Pharmacological Advances in Local Anaesthetics in Surgical Practice (2015)"))
story.append(H("Mechanism of Action:"))
story.append(B("Reversibly block voltage-gated Na⁺ channels → prevent action potential propagation → block in order: autonomic > sensory (pain, temp, touch) > motor."))
story.append(H("Common Local Anaesthetics:"))
data12 = [
    ["Agent","Type","Onset","Duration","Max Dose","Uses"],
    ["Lidocaine","Amide","Fast","1-2h","3 mg/kg (7 with adrenaline)","Infiltration, IV regional, topical"],
    ["Bupivacaine","Amide","Slow","4-8h","2 mg/kg","Spinal, epidural, peripheral nerve blocks"],
    ["Levobupivacaine","Amide","Slow","4-8h","2.5 mg/kg","Safer cardiac profile than bupivacaine"],
    ["Ropivacaine","Amide","Moderate","4-6h","3 mg/kg","Epidural, less motor block"],
    ["Prilocaine","Amide","Fast","2-3h","6 mg/kg","IVRA (Bier's block), lower toxicity"],
    ["Cocaine","Ester","Fast","1h","1.5 mg/kg","Topical ENT (vasoconstriction)"],
    ["Benzocaine","Ester","Fast","Short","Topical only","Topical mucosa"],
]
t12 = Table(data12, colWidths=[2.5*cm, 1.3*cm, 1.5*cm, 1.5*cm, 2.8*cm, 4.4*cm])
t12.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#1565c0')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),7.5),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#e3f2fd'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#90caf9')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t12)
story.append(H("Advances:"))
story.append(BL("Liposomal bupivacaine (Exparel): sustained release up to 72h, single injection wound infiltration"))
story.append(BL("Continuous peripheral nerve block catheters: improved post-op analgesia"))
story.append(BL("Ultrasound-guided regional anaesthesia: greater accuracy, less volume needed, fewer complications"))
story.append(BL("Adjuvants: dexamethasone (prolongs block 4-8h), dexmedetomidine, clonidine (α₂ agonist)"))
story.append(BL("EMLA cream: eutectic mixture of lidocaine 2.5% + prilocaine 2.5% – used for venepuncture analgesia"))
story.append(H("Toxicity (LAST – Local Anaesthetic Systemic Toxicity):"))
story.append(BL("CNS: perioral tingling → tinnitus → seizures → coma"))
story.append(BL("Cardiac: arrhythmias, cardiac arrest (bupivacaine worst)"))
story.append(BL("Treatment: STOP, 100% O₂, IV lipid emulsion 20% (Intralipid) 1.5 mL/kg bolus"))
story.append(N("Bailey & Love Ch. 14"))
story.append(HR())

# ---- Q56 ----
story.append(Q(56, "Regional Anaesthesia (2006)"))
story.append(H("Definition:"))
story.append(B("Interruption of nerve conduction over a region of the body using local anaesthetics, without loss of consciousness."))
story.append(H("Types:"))
story.append(BL("1. Central neuraxial blocks: Spinal (subarachnoid), Epidural, Caudal"))
story.append(BL("2. Peripheral nerve blocks: Brachial plexus (interscalene, supraclavicular, axillary), femoral, sciatic, ankle block"))
story.append(BL("3. Intravenous regional anaesthesia (Bier's block): upper limb surgery"))
story.append(BL("4. Plexus blocks: celiac, brachial, lumbar"))
story.append(BL("5. Field blocks and wound infiltration"))
story.append(H("Spinal vs. Epidural:"))
data13 = [
    ["Feature","Spinal","Epidural"],
    ["Space","Subarachnoid (CSF)","Epidural space"],
    ["Drug volume","Small (2-4 mL)","Large (10-20 mL)"],
    ["Onset","Fast (2-5 min)","Slow (15-20 min)"],
    ["Duration","Fixed (2-4h)","Continuous (catheter)"],
    ["Level","L2/3 or L3/4 (below cord)","Any level"],
    ["Dural puncture","Yes (intentional)","Accidental = headache"],
    ["Uses","Lower limb, perineal, abdominal","Labour, post-op analgesia"],
]
t13 = Table(data13, colWidths=[3*cm, 5.5*cm, 5.5*cm])
t13.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#1565c0')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),8.5),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#e3f2fd'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#90caf9')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t13)
story.append(H("Advantages of Regional over General Anaesthesia:"))
story.append(BL("Avoids airway instrumentation and GA risks"))
story.append(BL("Better post-op analgesia, less opioid use"))
story.append(BL("↓ PONV (post-operative nausea/vomiting)"))
story.append(BL("Earlier mobilisation, shorter hospital stay"))
story.append(BL("Reduced stress response to surgery"))
story.append(BL("Benefit in high-risk (cardiac/respiratory) patients"))
story.append(N("Bailey & Love Ch. 14"))
story.append(HR())

# ---- Q57 ----
story.append(Q(57, "Short Note on Epidural Anaesthesia"))
story.append(H("Anatomy:"))
story.append(BL("Epidural space: between ligamentum flavum and dura mater (contains fat, epidural veins, lymphatics)"))
story.append(BL("Extends from foramen magnum to sacral hiatus"))
story.append(H("Technique:"))
story.append(BL("Patient: sitting or lateral decubitus position"))
story.append(BL("Needle: Tuohy needle (16-18G), bevel upward"))
story.append(BL("Identification: 'loss of resistance' to air or saline technique"))
story.append(BL("Catheter: threaded 3-4 cm into epidural space for continuous infusion"))
story.append(BL("Test dose: 3 mL lidocaine 2% + adrenaline (detect intrathecal/intravascular placement)"))
story.append(H("Drugs Used:"))
story.append(BL("Bupivacaine 0.1-0.5% ± fentanyl/morphine opioid adjunct"))
story.append(BL("Low concentration = sensory block (labour analgesia)"))
story.append(BL("High concentration = motor + sensory block (surgery)"))
story.append(H("Complications:"))
story.append(BL("Dural puncture headache (PDPH): severe positional headache, Rx = bed rest, caffeine, blood patch"))
story.append(BL("High spinal block: hypotension, bradycardia, respiratory arrest"))
story.append(BL("Hypotension: treat with IV fluids, ephedrine 6mg IV"))
story.append(BL("Epidural haematoma: back pain → paraplegia (emergency MRI + decompression)"))
story.append(BL("Epidural abscess: fever + neurological deficit (MRI + antibiotics ± surgical drainage)"))
story.append(BL("Failed block: incomplete/patchy analgesia (~5-10%)"))
story.append(H("Uses in Surgery:"))
story.append(BL("Labour analgesia | Major abdominal/thoracic/lower limb surgery | Post-op pain (PCE)"))
story.append(N("Bailey & Love Ch. 14"))
story.append(HR())

# ---- Q58 ----
story.append(Q(58, "Incentive Spirometry (2008)"))
story.append(H("Definition:"))
story.append(B("Incentive spirometry (IS) is a respiratory therapy device that encourages patients to take slow, deep, sustained inspiratory efforts to prevent or treat atelectasis by providing visual feedback of inspiratory volume."))
story.append(H("Mechanism:"))
story.append(BL("Encourages diaphragmatic breathing → opens collapsed alveoli → increases FRC"))
story.append(BL("Generates negative intrathoracic pressure → sustains flow-volume loop → recruits atelectatic segments"))
story.append(H("Types:"))
story.append(BL("Volume-oriented (preferred): measures inspired volume (e.g. Voldyne) – target > 2500 mL"))
story.append(BL("Flow-oriented: visual balls indicating flow rate"))
story.append(H("Indications:"))
story.append(BL("Post-operative respiratory care (especially upper abdominal/thoracic surgery)"))
story.append(BL("Neuromuscular disease, atelectasis, COPD exacerbation, pneumonia"))
story.append(BL("Pre-operative conditioning in high-risk patients"))
story.append(H("Technique:"))
story.append(BL("Sit upright | Exhale normally | Seal lips around mouthpiece"))
story.append(BL("Inhale slowly and deeply | Hold 5-10 seconds | 10 breaths/hour while awake"))
story.append(H("Benefits:"))
story.append(BL("↓ Post-op pulmonary complications (pneumonia, atelectasis)"))
story.append(BL("↓ Length of hospital stay"))
story.append(BL("Improves FVC, FEV₁, SpO₂"))
story.append(H("Evidence:"))
story.append(BL("Strong for high-risk patients; less clear for routine low-risk cases"))
story.append(N("Bailey & Love Ch. 14 | Cochrane Review"))
story.append(HR())

# ---- Q59 ----
story.append(Q(59, "Management of Cardiac Arrest During Surgery (2023)"))
story.append(H("Causes in the Surgical Setting – 4Hs and 4Ts:"))
story.append(BL("4H: Hypoxia | Hypovolaemia | Hypo/Hyperkalaemia | Hypothermia"))
story.append(BL("4T: Tension pneumothorax | Tamponade | Thrombosis (PE/MI) | Toxins (drug error/LAST)"))
story.append(H("Surgical-Specific Causes:"))
story.append(BL("Haemorrhage/massive blood loss | Vagal reactions | Air embolism"))
story.append(BL("Positioning (supine hypotension) | Cement implantation syndrome"))
story.append(BL("Malignant hyperthermia (MH) | Local anaesthetic toxicity (LAST)"))
story.append(H("Immediate Management (ALS Algorithm):"))
story.append(BL("1. Recognise cardiac arrest: unresponsive, no pulse, no normal breathing"))
story.append(BL("2. Call for help / crash team"))
story.append(BL("3. Start CPR: 30:2 ratio, hard and fast (100-120 bpm, 5-6 cm depth)"))
story.append(BL("4. Secure airway: intubate early (anaesthetist usually present)"))
story.append(BL("5. IV/IO access: adrenaline 1 mg every 3-5 min"))
story.append(BL("6. Shockable rhythm (VF/pVT): defibrillate 200J biphasic immediately"))
story.append(BL("7. Amiodarone 300 mg IV after 3rd shock for VF/pVT"))
story.append(BL("8. Non-shockable (PEA/Asystole): CPR + adrenaline + treat reversible causes"))
story.append(H("If on Bypass: Cardiac surgery CPR differs – notify perfusionist"))
story.append(H("Special Situations:"))
story.append(BL("Malignant Hyperthermia: STOP trigger agent, Dantrolene 2.5 mg/kg IV, cooling"))
story.append(BL("LAST: 20% Intralipid 1.5 mL/kg IV"))
story.append(BL("Tension pneumothorax: needle decompression 2nd ICS MCL → chest drain"))
story.append(BL("Air embolism: left lateral Trendelenburg, aspirate via CVP, 100% O₂"))
story.append(N("Bailey & Love Ch. 14 | ALS Guidelines 2021 (Resuscitation Council UK)"))
story.append(HR())

# ---- Q60 ----
story.append(Q(60, "Pain Relief in Surgery / Post-Operative Pain Management (2009, 2011)"))
story.append(H("WHO Analgesic Ladder (adapted for post-op use):"))
story.append(BL("Step 1 (Mild pain): Non-opioids – Paracetamol 1g QDS + NSAIDs (ibuprofen, diclofenac, ketorolac)"))
story.append(BL("Step 2 (Moderate pain): Weak opioids – Codeine, Tramadol ± adjuvants"))
story.append(BL("Step 3 (Severe pain): Strong opioids – Morphine, Fentanyl, Oxycodone"))
story.append(H("Multimodal Analgesia (gold standard – reduces opioid use):"))
story.append(BL("Paracetamol + NSAID + Regional block + Opioid PRN"))
story.append(H("Routes and Delivery Methods:"))
story.append(BL("PCA (Patient-Controlled Analgesia): IV morphine self-administered within set lockout. Safe, patient autonomy."))
story.append(BL("Epidural analgesia: bupivacaine ± fentanyl – best for thoracic/abdominal surgery"))
story.append(BL("Peripheral nerve blocks: TAP block (abdominal), femoral/sciatic (lower limb), intercostal"))
story.append(BL("Wound infiltration: local anaesthetic at closure"))
story.append(BL("Oral route: as soon as tolerated post-op"))
story.append(H("Specific Analgesic Drugs:"))
data14 = [
    ["Drug","Mechanism","Dose","Notes"],
    ["Paracetamol","Central COX inhibition + serotonergic","1g QDS PO/IV","Safe, start ASAP"],
    ["NSAIDs","Peripheral COX-1/2 inhibition","Ketorolac 15-30 mg","Caution: renal, GI, bleeding"],
    ["Morphine","µ opioid receptor agonist","0.1 mg/kg IV titrated","Gold standard severe pain"],
    ["Fentanyl","µ agonist, rapid onset","1-2 mcg/kg","Patch for chronic, IV for acute"],
    ["Gabapentin","Voltage-gated Ca²⁺ channel (α₂δ)","300 mg TDS","Pre-op gabapentin reduces opioid use"],
    ["Ketamine","NMDA antagonist","Sub-anaesthetic 0.1-0.5 mg/kg","Opioid-sparing, useful in chronic pain"],
    ["Dexamethasone","Anti-inflammatory, antiemetic","4-8 mg IV","Reduces PONV + extends nerve block"],
]
t14 = Table(data14, colWidths=[2.8*cm, 4*cm, 3*cm, 4.2*cm])
t14.setStyle(TableStyle([
    ('BACKGROUND',(0,0),(-1,0),colors.HexColor('#1565c0')),
    ('TEXTCOLOR',(0,0),(-1,0),colors.white),
    ('FONTNAME',(0,0),(-1,0),'Helvetica-Bold'),
    ('FONTSIZE',(0,0),(-1,-1),7.5),
    ('ROWBACKGROUNDS',(0,1),(-1,-1),[colors.HexColor('#e3f2fd'),colors.white]),
    ('GRID',(0,0),(-1,-1),0.4,colors.HexColor('#90caf9')),
    ('VALIGN',(0,0),(-1,-1),'MIDDLE'),
    ('TOPPADDING',(0,0),(-1,-1),3),
    ('BOTTOMPADDING',(0,0),(-1,-1),3),
]))
story.append(t14)
story.append(H("ERAS (Enhanced Recovery After Surgery) Pain Principles:"))
story.append(BL("Pre-emptive analgesia (pre-op gabapentin/NSAID) | Minimal opioids | Early mobilisation | Avoid immobility"))
story.append(N("Bailey & Love Ch. 14"))
story.append(HR())

# ---- Q61 ----
story.append(Q(61, "Invasive and Non-Invasive Techniques of Post-Operative Analgesia (2021)"))
story.append(H("NON-INVASIVE TECHNIQUES:"))
story.append(BL("1. Oral analgesics: paracetamol, NSAIDs, opioids, gabapentinoids, ketamine"))
story.append(BL("2. Transdermal patches: fentanyl patch (72h), buprenorphine patch – for chronic/cancer pain"))
story.append(BL("3. Inhaled analgesia: Entonox (50% N₂O + 50% O₂) – labour, dressing changes"))
story.append(BL("4. TENS (Transcutaneous electrical nerve stimulation): gate control theory – mild pain"))
story.append(BL("5. Ice/cold therapy: reduces inflammation, local analgesia post-op"))
story.append(BL("6. Psychological: distraction, guided imagery, music therapy"))
story.append(H("INVASIVE TECHNIQUES:"))
story.append(BL("1. IV PCA (Patient Controlled Analgesia): morphine 1mg bolus, 5 min lockout, 24h limit"))
story.append(BL("2. IV infusions: morphine/fentanyl continuous infusion (ICU setting)"))
story.append(BL("3. Epidural analgesia (PCE): bupivacaine + fentanyl via catheter; gold standard for major surgery"))
story.append(BL("4. Spinal opioids: intrathecal morphine 0.1-0.3 mg at time of spinal – 12-24h analgesia"))
story.append(BL("5. Peripheral nerve blocks (single shot or catheter):"))
story.append(BL("   - TAP block: somatic pain after abdominal surgery"))
story.append(BL("   - Femoral nerve block: hip/knee surgery"))
story.append(BL("   - Sciatic nerve block: foot/ankle surgery"))
story.append(BL("   - Brachial plexus block: upper limb surgery"))
story.append(BL("   - Intercostal nerve block: rib fractures, thoracotomy"))
story.append(BL("   - Paravertebral block: unilateral analgesia for mastectomy/thoracic surgery"))
story.append(BL("6. Wound infiltration: continuous wound infusion catheters"))
story.append(BL("7. Intra-articular injection: morphine/bupivacaine into joint space (knee arthroscopy)"))
story.append(H("Monitoring Post-Op Analgesia:"))
story.append(BL("Pain scores (NRS 0-10 or VAS) | Sedation score | Respiratory rate | PONV"))
story.append(N("Bailey & Love Ch. 14"))
story.append(HR())

# FOOTER
story.append(Spacer(1, 0.5*cm))
story.append(Paragraph("— END OF DOCUMENT —", subtitle_style))
story.append(Paragraph("Bailey and Love's Short Practice of Surgery, 28th Edition (2023) | MS General Surgery Exam Preparation", note_style))
story.append(Paragraph("Questions 37–61 | Chapters 2 (Shock & Trauma), 4 (Blood Transfusion & Coagulation), 14 (Anaesthesia & Critical Care)", note_style))

doc.build(story)
print(f"PDF generated: {OUTPUT}")

<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>MS Surgery Exam – Q37–61 | Bailey & Love</title>
<style>
  :root {
    --blue: #1565c0;
    --red: #b71c1c;
    --lblue: #e3f2fd;
    --lred: #ffebee;
    --text: #212121;
    --muted: #546e7a;
  }
  * { box-sizing: border-box; margin: 0; padding: 0; }
  body { font-family: 'Segoe UI', Arial, sans-serif; font-size: 14px; color: var(--text); background: #fafafa; padding: 10px; }
  .cover { text-align: center; background: var(--blue); color: white; padding: 24px 16px; border-radius: 8px; margin-bottom: 18px; }
  .cover h1 { font-size: 22px; letter-spacing: 1px; }
  .cover h2 { font-size: 15px; font-weight: 400; margin-top: 6px; opacity: 0.9; }
  .cover p { font-size: 12px; margin-top: 8px; opacity: 0.75; }
  .section-header { background: var(--blue); color: white; font-size: 15px; font-weight: 700; padding: 8px 14px; border-radius: 6px; margin: 22px 0 10px 0; letter-spacing: 0.5px; }
  .question { background: #fff3e0; border-left: 5px solid var(--red); padding: 8px 12px; margin: 16px 0 6px 0; border-radius: 0 6px 6px 0; }
  .question .qnum { color: var(--red); font-weight: 800; font-size: 15px; }
  .question .qtitle { color: var(--red); font-weight: 700; font-size: 14px; }
  .h3 { color: var(--blue); font-weight: 700; font-size: 13px; margin: 10px 0 4px 0; border-bottom: 1px solid var(--lblue); padding-bottom: 2px; }
  p.body { line-height: 1.6; margin: 4px 0; }
  ul { padding-left: 18px; margin: 4px 0; }
  ul li { margin: 3px 0; line-height: 1.5; }
  table { width: 100%; border-collapse: collapse; margin: 8px 0; font-size: 12px; }
  th { background: var(--blue); color: white; padding: 5px 7px; text-align: left; font-weight: 700; }
  tr:nth-child(even) td { background: var(--lblue); }
  tr:nth-child(odd) td { background: white; }
  td { padding: 4px 7px; border: 1px solid #90caf9; vertical-align: top; line-height: 1.4; }
  table.red th { background: var(--red); }
  table.red tr:nth-child(even) td { background: var(--lred); }
  table.red td { border-color: #ef9a9a; }
  .note { font-size: 11px; color: var(--muted); font-style: italic; margin: 6px 0 12px 0; padding: 4px 8px; border-left: 3px solid #90caf9; }
  hr { border: none; border-top: 1px solid #90caf9; margin: 16px 0; }
  .print-btn { display: block; text-align: center; background: var(--red); color: white; padding: 14px; border-radius: 8px; font-size: 16px; font-weight: 700; margin: 20px 0; cursor: pointer; border: none; width: 100%; }
  .tip { background: #e8f5e9; border-left: 4px solid #43a047; padding: 10px 14px; border-radius: 0 6px 6px 0; font-size: 13px; margin-bottom: 16px; }
  @media print {
    .print-btn, .tip { display: none; }
    body { background: white; padding: 0; font-size: 11px; }
    .section-header { background: #333 !important; -webkit-print-color-adjust: exact; print-color-adjust: exact; }
    th { background: #333 !important; -webkit-print-color-adjust: exact; print-color-adjust: exact; }
  }
</style>
</head>
<body>

<div class="cover">
  <h1>MS GENERAL SURGERY</h1>
  <h2>EXAM-READY STRUCTURED ANSWERS &mdash; Q37 to Q61</h2>
  <p>Bailey &amp; Love&rsquo;s Short Practice of Surgery, 28th Edition &bull; ~15 min per answer &bull; All key scoring points</p>
</div>

<div class="tip">
  <strong>📱 To save as PDF on your phone:</strong><br>
  Tap the <strong>"Save / Print as PDF"</strong> button below &rarr; your browser will open a print dialog &rarr; choose <strong>"Save as PDF"</strong> (or "PDF" destination).
</div>

<button class="print-btn" onclick="window.print()">📄 Save / Print as PDF</button>

<!-- ===== SECTION A ===== -->
<div class="section-header">SECTION A &mdash; SHOCK &amp; SEPSIS &nbsp;(Q37&ndash;41)</div>

<div class="question"><span class="qnum">Q37. </span><span class="qtitle">Criteria of SIRS (2013, 2021)</span></div>
<div class="h3">Definition</div>
<p class="body">SIRS = Systemic Inflammatory Response Syndrome. A non-specific clinical response to a severe insult (infectious or non-infectious).</p>
<div class="h3">Diagnostic Criteria &mdash; ANY 2 of 4:</div>
<table>
<tr><th>Parameter</th><th>Abnormal Value</th></tr>
<tr><td>Temperature</td><td>&gt; 38&deg;C &nbsp;OR&nbsp; &lt; 36&deg;C</td></tr>
<tr><td>Heart Rate</td><td>&gt; 90 bpm</td></tr>
<tr><td>Respiratory Rate</td><td>&gt; 20 breaths/min &nbsp;OR&nbsp; PaCO&sub2; &lt; 4.3 kPa (32 mmHg)</td></tr>
<tr><td>WBC Count</td><td>&gt; 12,000/mm&sup3; &nbsp;OR&nbsp; &lt; 4,000/mm&sup3; &nbsp;OR&nbsp; &gt;10% bands</td></tr>
</table>
<div class="h3">Sepsis-3 Definitions (2016, tested as 2021 update):</div>
<ul>
<li><strong>Sepsis</strong> = life-threatening organ dysfunction from dysregulated host response to infection</li>
<li><strong>Organ dysfunction</strong> = SOFA score increase &ge; 2 points</li>
<li><strong>Septic shock</strong> = Sepsis + vasopressor requirement + lactate &gt; 2 mmol/L despite fluids</li>
<li><strong>qSOFA</strong> (bedside): RR &ge; 22, altered mentation, SBP &le; 100 &mdash; 2 of 3 = suspect sepsis</li>
</ul>
<div class="h3">Progression:</div>
<p class="body">SIRS &rarr; Sepsis &rarr; Severe Sepsis &rarr; Septic Shock &rarr; MODS</p>
<div class="note">Bailey &amp; Love Ch.2 | Sepsis-3 (Singer et al., JAMA 2016)</div>
<hr>

<div class="question"><span class="qnum">Q38. </span><span class="qtitle">Pathogenesis of Sepsis-Induced Hypotension (2014)</span></div>
<div class="h3">Mechanism:</div>
<p class="body">Infection &rarr; PRR/TLR activation &rarr; NF-&kappa;B &rarr; Cytokine storm (TNF-&alpha;, IL-1&beta;, IL-6) &rarr; Cardiovascular dysfunction</p>
<ul>
<li>iNOS upregulation &rarr; excess <strong>Nitric Oxide</strong> &rarr; profound vasodilation &rarr; &darr; SVR</li>
<li>Endothelial injury &rarr; capillary leak &rarr; intravascular hypovolaemia</li>
<li>Myocardial depression: TNF-&alpha; + IL-1&beta; suppress contractility</li>
<li>Relative adrenal insufficiency in prolonged sepsis</li>
<li>Mitochondrial dysfunction &rarr; cellular dysoxia</li>
</ul>
<div class="h3">Haemodynamic Profile of Septic Shock:</div>
<table>
<tr><th>Parameter</th><th>Early (Warm)</th><th>Late (Cold)</th></tr>
<tr><td>Cardiac Output</td><td>&uarr; High</td><td>&darr; Low</td></tr>
<tr><td>SVR</td><td>&darr; Low</td><td>&darr;&darr; Very Low</td></tr>
<tr><td>PCWP</td><td>Low</td><td>Low</td></tr>
<tr><td>Mixed venous O&sub2;</td><td>High</td><td>Low</td></tr>
</table>
<div class="h3">Management &mdash; Surviving Sepsis Hour-1 Bundle:</div>
<ul>
<li>Measure lactate (re-measure if &gt; 2 mmol/L)</li>
<li>Blood cultures &times; 2 before antibiotics</li>
<li>Broad-spectrum antibiotics within 1 hour</li>
<li>30 mL/kg IV crystalloid for hypotension or lactate &ge; 4</li>
<li>Vasopressor if MAP &lt; 65 mmHg: <strong>Noradrenaline</strong> (1st line)</li>
</ul>
<div class="note">Bailey &amp; Love Ch.2 | Surviving Sepsis Campaign 2021</div>
<hr>

<div class="question"><span class="qnum">Q39. </span><span class="qtitle">Distributive Shock (2014)</span></div>
<div class="h3">Definition:</div>
<p class="body">Maldistribution of blood flow due to pathological vasodilation &rarr; high CO + low SVR &rarr; tissue hypoperfusion despite adequate circulating volume.</p>
<div class="h3">Types:</div>
<ul>
<li><strong>Septic shock</strong> (most common) &mdash; NO-mediated vasodilation</li>
<li><strong>Anaphylactic shock</strong> &mdash; IgE-mediated histamine/leukotriene release</li>
<li><strong>Neurogenic shock</strong> &mdash; spinal injury T6+ &rarr; loss of sympathetic tone + bradycardia</li>
<li><strong>Toxic shock syndrome</strong> &mdash; superantigen-mediated cytokine storm</li>
</ul>
<div class="h3">Classic Haemodynamic Profile:</div>
<p class="body">&uarr; CO | &darr; SVR | &darr; PCWP | &uarr; Mixed venous O&sub2; | Warm extremities</p>
<div class="h3">Management:</div>
<ul>
<li><strong>Septic:</strong> Antibiotics + IV fluids + Noradrenaline</li>
<li><strong>Anaphylactic:</strong> IM Adrenaline 0.5 mg (1:1000) + IV fluids + steroids + antihistamines</li>
<li><strong>Neurogenic:</strong> IV fluids + vasopressors (phenylephrine) + atropine for bradycardia</li>
</ul>
<div class="note">Bailey &amp; Love Ch.2, Table 2.1</div>
<hr>

<div class="question"><span class="qnum">Q40. </span><span class="qtitle">Biomarkers of Sepsis (2023)</span></div>
<table>
<tr><th>Biomarker</th><th>Normal</th><th>Sepsis Value</th><th>Role</th></tr>
<tr><td><strong>Procalcitonin (PCT)</strong></td><td>&lt; 0.1 ng/mL</td><td>&gt; 2 ng/mL</td><td>Diagnosis; antibiotic de-escalation</td></tr>
<tr><td>C-Reactive Protein</td><td>&lt; 10 mg/L</td><td>&gt; 100 mg/L</td><td>Diagnosis &amp; monitoring</td></tr>
<tr><td><strong>Lactate</strong></td><td>&lt; 2 mmol/L</td><td>&gt; 2 mmol/L</td><td>Tissue hypoxia; prognosis</td></tr>
<tr><td>IL-6</td><td>Low</td><td>&gt; 1000 pg/mL</td><td>Early sepsis marker</td></tr>
<tr><td>Presepsin (sCD14-ST)</td><td>&lt; 300 pg/mL</td><td>Elevated</td><td>Early macrophage activation</td></tr>
<tr><td>sTREM-1</td><td>Low</td><td>Elevated</td><td>Amplifies inflammatory signal</td></tr>
<tr><td>Blood cultures</td><td>Sterile</td><td>Growth</td><td>Gold standard &mdash; definitive</td></tr>
</table>
<div class="h3">Procalcitonin Key Points:</div>
<ul>
<li>Rises 2&ndash;4h after bacterial infection (faster than CRP)</li>
<li>Does NOT rise in viral infection or autoimmune disease</li>
<li>PCT-guided therapy reduces antibiotic duration by ~3 days</li>
<li>PCT &lt; 0.5 ng/mL = consider stopping antibiotics</li>
</ul>
<div class="note">Bailey &amp; Love Ch.2 | Sepsis-3 2016</div>
<hr>

<div class="question"><span class="qnum">Q41. </span><span class="qtitle">Pathophysiology and Management of Haemorrhagic Shock</span></div>
<div class="h3">ATLS Classification of Haemorrhage:</div>
<table class="red">
<tr><th>Class</th><th>Blood Loss</th><th>% BV</th><th>HR</th><th>BP</th><th>RR</th><th>Urine mL/h</th><th>CNS</th></tr>
<tr><td>I</td><td>&lt; 750 mL</td><td>&lt; 15%</td><td>&lt; 100</td><td>Normal</td><td>14&ndash;20</td><td>&gt; 30</td><td>Normal</td></tr>
<tr><td>II</td><td>750&ndash;1500</td><td>15&ndash;30%</td><td>100&ndash;120</td><td>Normal</td><td>20&ndash;30</td><td>20&ndash;30</td><td>Anxious</td></tr>
<tr><td>III</td><td>1500&ndash;2000</td><td>30&ndash;40%</td><td>120&ndash;140</td><td>&darr;</td><td>30&ndash;40</td><td>5&ndash;20</td><td>Confused</td></tr>
<tr><td>IV</td><td>&gt; 2000 mL</td><td>&gt; 40%</td><td>&gt; 140</td><td>&darr;&darr;</td><td>&gt; 35</td><td>&lt; 5</td><td>Lethargic</td></tr>
</table>
<div class="h3">Pathophysiology:</div>
<ul>
<li>&darr; Circulating volume &rarr; &darr; Preload &rarr; &darr; CO &rarr; &darr; MAP</li>
<li>Compensatory: &uarr; HR, &uarr; SVR, ADH release, RAAS activation</li>
<li>Prolonged: ischaemia &rarr; acidosis &rarr; <strong>Lethal Triad</strong> (Hypothermia + Acidosis + Coagulopathy)</li>
</ul>
<div class="h3">Management &mdash; Damage Control Resuscitation:</div>
<ul>
<li><strong>Stop the bleeding</strong> (surgical/interventional) &mdash; PRIMARY goal</li>
<li>Permissive hypotension: target MAP 50&ndash;65 mmHg until surgical control</li>
<li>Haemostatic resuscitation: pRBC : FFP : Platelets = <strong>1:1:1</strong></li>
<li><strong>Tranexamic acid 1g IV</strong> within 3 hours (CRASH-2 trial)</li>
<li>Warm fluids + warming blanket</li>
<li>Calcium replacement</li>
<li>Limit crystalloids (avoid dilutional coagulopathy)</li>
</ul>
<div class="h3">Endpoints of Resuscitation:</div>
<p class="body">Lactate &lt; 2 mmol/L | Base excess &gt; -6 | Urine output &gt; 0.5 mL/kg/h | Normal coagulation</p>
<div class="note">Bailey &amp; Love Ch.2 | CRASH-2 Trial | ATLS 10th Ed</div>
<hr>

<!-- ===== SECTION B ===== -->
<div class="section-header">SECTION B &mdash; BLOOD COAGULATION &nbsp;(Q42&ndash;44)</div>

<div class="question"><span class="qnum">Q42. </span><span class="qtitle">Physiology of Blood Coagulation and Its Importance in Surgery (2024)</span></div>
<div class="h3">Primary Haemostasis:</div>
<ul>
<li>Injury &rarr; vascular spasm &rarr; platelet adhesion (vWF to collagen via GPIb)</li>
<li>Platelet activation: shape change + release of ADP, TXA&sub2;, serotonin</li>
<li>Platelet aggregation: GPIIb/IIIa binds fibrinogen &rarr; platelet plug</li>
</ul>
<div class="h3">Secondary Haemostasis &mdash; Cell-Based Model:</div>
<ul>
<li><strong>Initiation:</strong> TF + FVIIa &rarr; FXa + FIXa &rarr; small thrombin burst</li>
<li><strong>Amplification:</strong> thrombin activates FV, FVIII, FXI, platelets</li>
<li><strong>Propagation:</strong> tenase (FIXa/FVIIIa) + prothrombinase (FXa/FVa) &rarr; large thrombin burst &rarr; fibrin</li>
</ul>
<div class="h3">Classic Cascade:</div>
<table>
<tr><th>Pathway</th><th>Factors</th><th>Test</th></tr>
<tr><td>Intrinsic (contact)</td><td>XII &rarr; XI &rarr; IX &rarr; X</td><td>APTT</td></tr>
<tr><td>Extrinsic (TF)</td><td>VII &rarr; X</td><td>PT / INR</td></tr>
<tr><td>Common</td><td>X &rarr; Thrombin &rarr; Fibrin</td><td>Both</td></tr>
</table>
<div class="h3">Fibrinolysis:</div>
<ul>
<li>tPA &rarr; plasminogen &rarr; plasmin &rarr; cleaves fibrin &rarr; FDPs / D-dimers</li>
<li>Regulated by PAI-1 (inhibits tPA) and &alpha;&sub2;-antiplasmin</li>
</ul>
<div class="h3">Surgical Importance:</div>
<ul>
<li>Pre-op: coagulation screen (PT, APTT, platelets, bleeding time)</li>
<li>Intra-op: diathermy, ligature, topical agents (Surgicel, Gelfoam)</li>
<li>Post-op: DVT prophylaxis (LMWH + TED stockings) vs. bleeding risk</li>
<li>Drug effects: Warfarin (blocks II, VII, IX, X) | Aspirin (irreversible COX-1) | NOACs</li>
</ul>
<div class="note">Bailey &amp; Love Ch.4 &amp; Ch.2</div>
<hr>

<div class="question"><span class="qnum">Q43. </span><span class="qtitle">Coagulation Disorders and Their Management</span></div>
<table>
<tr><th>Disorder</th><th>Defect</th><th>PT</th><th>APTT</th><th>Plt</th><th>Treatment</th></tr>
<tr><td>Haemophilia A</td><td>Factor VIII deficiency</td><td>N</td><td>&uarr;</td><td>N</td><td>Factor VIII conc / DDAVP</td></tr>
<tr><td>Haemophilia B</td><td>Factor IX deficiency</td><td>N</td><td>&uarr;</td><td>N</td><td>Factor IX concentrate</td></tr>
<tr><td>vWD</td><td>vWF def/dysfunction</td><td>N</td><td>&uarr;/N</td><td>N/&darr;</td><td>DDAVP / cryoprecipitate</td></tr>
<tr><td><strong>DIC</strong></td><td>Consumption of all factors</td><td>&uarr;</td><td>&uarr;</td><td>&darr;</td><td>Treat cause + FFP + cryo + plt</td></tr>
<tr><td>Liver disease</td><td>Reduced factor synthesis</td><td>&uarr;</td><td>&uarr;</td><td>&darr;</td><td>Vit K, FFP, platelets</td></tr>
<tr><td>Warfarin OD</td><td>Vit K-dep factors &darr;</td><td>&uarr;</td><td>N/&uarr;</td><td>N</td><td>Vit K + PCC (4-factor)</td></tr>
<tr><td>ITP</td><td>Anti-platelet Ab</td><td>N</td><td>N</td><td>&darr;</td><td>Steroids, IVIG, splenectomy</td></tr>
</table>
<div class="h3">DIC Key Points:</div>
<ul>
<li>Triggers: sepsis, trauma, obstetric emergencies, malignancy</li>
<li>Lab: &uarr;PT, &uarr;APTT, &darr;Fibrinogen, &darr;Platelets, &uarr;D-dimer, &uarr;FDPs</li>
<li>Management: <strong>TREAT THE CAUSE</strong> + FFP + cryoprecipitate + platelets</li>
</ul>
<div class="note">Bailey &amp; Love Ch.4</div>
<hr>

<div class="question"><span class="qnum">Q44. </span><span class="qtitle">Coagulopathy in Trauma Patients (2021)</span></div>
<div class="h3">Acute Traumatic Coagulopathy (ATC):</div>
<ul>
<li>Occurs within minutes of injury in up to 25% of trauma patients</li>
<li>4-fold increase in mortality</li>
<li>Driven by: shock + tissue injury &rarr; protein C activation &rarr; anticoagulation + hyperfibrinolysis</li>
</ul>
<div class="h3">Lethal Triad (Trauma-Induced Coagulopathy):</div>
<table class="red">
<tr><th>Component</th><th>Effect</th><th>Critical Threshold</th></tr>
<tr><td>Hypothermia</td><td>Impairs enzymatic coagulation</td><td>&lt; 34&deg;C</td></tr>
<tr><td>Acidosis</td><td>Inhibits thrombin generation, platelet function</td><td>pH &lt; 7.2</td></tr>
<tr><td>Haemodilution</td><td>Dilutes clotting factors &amp; platelets</td><td>After &gt; 10 units pRBC</td></tr>
</table>
<div class="h3">Assessment:</div>
<ul>
<li><strong>ROTEM / TEG</strong> (thromboelastography) &mdash; bedside viscoelastic testing, gold standard</li>
<li>Conventional: PT, APTT, fibrinogen, platelet count, D-dimer</li>
</ul>
<div class="h3">Damage Control Resuscitation (DCR):</div>
<ul>
<li>1:1:1 ratio pRBC:FFP:Platelets (PROPPR trial)</li>
<li><strong>Tranexamic acid 1g IV</strong> within 3 hours (CRASH-2)</li>
<li>Fibrinogen / cryoprecipitate if fibrinogen &lt; 1.5 g/L</li>
<li>Calcium replacement (citrate chelates Ca&sup2;&plus;)</li>
<li>Damage Control Surgery: temporary haemostasis, pack, close, return for definitive repair</li>
<li>Avoid excess crystalloid</li>
</ul>
<div class="note">Bailey &amp; Love Ch.2 | PROPPR Trial | CRASH-2 Trial</div>
<hr>

<!-- ===== SECTION C ===== -->
<div class="section-header">SECTION C &mdash; BLOOD TRANSFUSION &nbsp;(Q45&ndash;54)</div>

<div class="question"><span class="qnum">Q45. </span><span class="qtitle">Blood Component Separation and Their Role in Surgery (2016, 2017)</span></div>
<table>
<tr><th>Component</th><th>Contents</th><th>Storage</th><th>Surgical Indication</th></tr>
<tr><td><strong>pRBC</strong></td><td>RBCs, minimal plasma</td><td>4&deg;C, 35&ndash;42 days</td><td>Anaemia, haemorrhage (Hb &lt; 7)</td></tr>
<tr><td><strong>FFP</strong></td><td>All clotting factors</td><td>&minus;30&deg;C, 1 year</td><td>DIC, massive transfusion, warfarin reversal</td></tr>
<tr><td><strong>Platelets</strong></td><td>Platelets in plasma</td><td>22&deg;C agitated, 5&ndash;7 days</td><td>Plt &lt; 50k pre-op; &lt; 10k prophylactic</td></tr>
<tr><td><strong>Cryoprecipitate</strong></td><td>FVIII, vWF, Fibrinogen, FXIII</td><td>&minus;30&deg;C, 1 year</td><td>Haemophilia A, vWD, DIC, TIC</td></tr>
<tr><td>Albumin</td><td>Colloid protein</td><td>Room temp</td><td>Hypoalbuminaemia, SBP treatment</td></tr>
<tr><td>Factor Concentrates</td><td>Specific factors</td><td>Varied</td><td>Haemophilia (FVIIIc, FIXc), PCC</td></tr>
</table>
<div class="h3">Leucodepletion (universal in UK since 1999):</div>
<ul>
<li>Prevents febrile non-haemolytic reactions, CMV, vCJD, HLA alloimmunisation</li>
</ul>
<div class="h3">Irradiation:</div>
<ul>
<li>Prevents TA-GvHD in immunocompromised patients</li>
</ul>
<div class="note">Bailey &amp; Love Ch.4</div>
<hr>

<div class="question"><span class="qnum">Q46. </span><span class="qtitle">Blood Substitutes and Changes in Stored Blood (2011, 2023)</span></div>
<div class="h3">Storage Lesion (Changes in Stored Blood):</div>
<table>
<tr><th>Change</th><th>Clinical Effect</th></tr>
<tr><td>&darr; 2,3-DPG</td><td>Left shift O&sub2; curve &rarr; impaired O&sub2; release to tissues</td></tr>
<tr><td>&uarr; K&plus; (hyperkalaemia)</td><td>RBC lysis &rarr; cardiac arrhythmias in massive transfusion</td></tr>
<tr><td>&darr; pH (acidosis)</td><td>CO&sub2; + lactate accumulation</td></tr>
<tr><td>&uarr; Microaggregates</td><td>Microthrombi formation</td></tr>
<tr><td>&darr; Factor V, VIII</td><td>Labile factors degrade (only retained in FFP)</td></tr>
<tr><td>&uarr; Citrate</td><td>Chelates Ca&sup2;&plus; &rarr; hypocalcaemia in massive transfusion</td></tr>
<tr><td>Hypothermia effect</td><td>Cold blood &rarr; cardiac arrhythmias</td></tr>
</table>
<div class="h3">Blood Substitutes (HBOCs &amp; PFCs):</div>
<ul>
<li><strong>HBOCs</strong> (e.g. Hemopure): polymerised Hb &rarr; carries O&sub2;, no cross-matching needed</li>
<li><strong>Perfluorocarbons</strong>: dissolve O&sub2;, require high FiO&sub2;</li>
<li>Limitations: vasoconstriction, oxidative stress, short half-life &mdash; not yet routine use</li>
<li>Future: recombinant Hb, nano-RBCs, universal donor RBCs</li>
</ul>
<div class="note">Bailey &amp; Love Ch.4</div>
<hr>

<div class="question"><span class="qnum">Q47. </span><span class="qtitle">How Will You Assess the Amount of Blood Loss in a Surgical Patient? (2021)</span></div>
<div class="h3">A. Clinical Assessment:</div>
<ul>
<li>Vital signs: HR, BP, RR, pulse pressure, capillary refill &gt; 2 sec, urine output</li>
<li>ATLS Classes I&ndash;IV (see Q41)</li>
<li>Shock Index = HR / SBP | Normal 0.5&ndash;0.7 | &gt; 1.0 = significant haemorrhage</li>
</ul>
<div class="h3">B. Investigations:</div>
<ul>
<li>FBC: Hb (note: early haemorrhage Hb may be normal)</li>
<li>ABG: Lactate, Base deficit (&gt; &minus;6 = significant shock)</li>
<li>Coagulation profile: PT, APTT, fibrinogen</li>
<li>Cross-match / Group &amp; Save</li>
</ul>
<div class="h3">C. Quantitative Methods:</div>
<ul>
<li>Swab weighing (1 g = 1 mL blood)</li>
<li>Suction canister measurement</li>
<li>EBL formula = EBV &times; (initial Hct &minus; final Hct) / initial Hct</li>
<li>EBV: 70 mL/kg adult | 80&ndash;85 mL/kg child</li>
</ul>
<div class="note">Bailey &amp; Love Ch.2 &amp; Ch.4</div>
<hr>

<div class="question"><span class="qnum">Q48. </span><span class="qtitle">Classification, Indications and Complications of Allogeneic Blood Transfusion (2025)</span></div>
<div class="h3">Indications:</div>
<ul>
<li>Symptomatic anaemia unresponsive to medical treatment</li>
<li>Acute haemorrhage Class III/IV; Hb &lt; 7 g/dL (&lt; 8 in cardiac disease)</li>
<li>Platelets &lt; 10 &times; 10&sup9;/L prophylactic; &lt; 50 &times; 10&sup9;/L pre-operative</li>
<li>Coagulopathy: FFP if PT/APTT &gt; 1.5&times; normal; Cryo if fibrinogen &lt; 1.5 g/L</li>
</ul>
<div class="h3">Complications (SHOT Classification):</div>
<table class="red">
<tr><th>Type</th><th>Reaction</th><th>Mechanism</th><th>Management</th></tr>
<tr><td>Acute</td><td><strong>Acute haemolytic</strong></td><td>ABO incompatibility</td><td>STOP, fluids, frusemide, FFP</td></tr>
<tr><td>Acute</td><td>FNHTR</td><td>WBC antibodies</td><td>Paracetamol, slow rate</td></tr>
<tr><td>Acute</td><td>Anaphylaxis</td><td>IgA deficiency</td><td>Adrenaline, steroids, antihistamines</td></tr>
<tr><td>Acute</td><td><strong>TACO</strong></td><td>Volume overload</td><td>Diuretics, O&sub2;, upright position</td></tr>
<tr><td>Acute</td><td><strong>TRALI</strong></td><td>Anti-HLA/HNA Ab</td><td>O&sub2;, ventilatory support, ICU</td></tr>
<tr><td>Acute</td><td>Septic shock</td><td>Bacterial contamination</td><td>Blood culture, IV antibiotics</td></tr>
<tr><td>Delayed</td><td>Delayed haemolytic</td><td>Amnestic Ab response</td><td>Monitor renal function</td></tr>
<tr><td>Delayed</td><td>TA-GvHD</td><td>Donor T-cells attack host</td><td>Irradiation (prevention only)</td></tr>
<tr><td>Delayed</td><td>Iron overload</td><td>Repeated transfusion</td><td>Desferrioxamine chelation</td></tr>
</table>
<div class="note">Bailey &amp; Love Ch.4 | SHOT Annual Report</div>
<hr>

<div class="question"><span class="qnum">Q49. </span><span class="qtitle">Autologous Blood Transfusion &mdash; Types and Advantages (2021, 2022)</span></div>
<div class="h3">Types:</div>
<ul>
<li><strong>1. Pre-operative autologous donation (PAD):</strong> collect 2&ndash;4 weeks before elective surgery; stored refrigerated.</li>
<li><strong>2. Acute normovolaemic haemodilution (ANH):</strong> remove blood at start of surgery, replace with crystalloid, re-infuse at end.</li>
<li><strong>3. Intra-operative cell salvage (ICS):</strong> suction blood from field &rarr; wash &rarr; re-infuse. Used in cardiac, vascular, orthopaedic surgery.</li>
<li><strong>4. Post-operative wound drainage salvage:</strong> collect drain blood, filter, re-infuse within 6 hours.</li>
</ul>
<div class="h3">Advantages:</div>
<ul>
<li>Eliminates risk of alloimmunisation, infectious transmission, TRALI, TA-GvHD</li>
<li>Reduces allogeneic blood demand</li>
<li>Fresh, 2,3-DPG replete blood (cell salvage)</li>
<li>Acceptable to Jehovah's Witnesses (cell salvage)</li>
</ul>
<div class="h3">Contraindications for Cell Salvage:</div>
<ul>
<li>Malignant field (relative) | Bowel contamination | Amniotic fluid (relative)</li>
</ul>
<div class="note">Bailey &amp; Love Ch.4</div>
<hr>

<div class="question"><span class="qnum">Q50. </span><span class="qtitle">Massive Blood Transfusion &mdash; Definition, Complications, Management (2022)</span></div>
<div class="h3">Definition (any one):</div>
<ul>
<li>&ge; 10 units pRBC in 24 hours</li>
<li>Replacement of entire blood volume in 24 hours</li>
<li>&gt; 4 units pRBC in 1 hour with anticipated continued need</li>
</ul>
<div class="h3">Complications:</div>
<ul>
<li>Dilutional coagulopathy (&darr; clotting factors, &darr; platelets)</li>
<li>Hypocalcaemia (citrate chelates Ca&sup2;&plus;) &rarr; myocardial depression</li>
<li>Hyperkalaemia &rarr; arrhythmias</li>
<li>Hypothermia &rarr; enzyme inhibition</li>
<li>Metabolic acidosis (lactate + citrate)</li>
<li>TACO, TRALI</li>
</ul>
<div class="h3">Management &mdash; Massive Haemorrhage Protocol (MHP):</div>
<ul>
<li>Activate MHP: alert haematology, blood bank, consultant</li>
<li>Empiric <strong>1:1:1 pRBC:FFP:Platelets</strong></li>
<li>Tranexamic acid 1g IV stat + 1g over 8h</li>
<li>Calcium gluconate 10 mL 10% IV after every 4 units pRBC</li>
<li>Warm blood (in-line warmer, target &gt; 37&deg;C)</li>
<li>ROTEM/TEG-guided product use</li>
<li>Cryoprecipitate if fibrinogen &lt; 1.5 g/L (target &gt; 2 g/L)</li>
<li>rFVIIa (NovoSeven) as last resort</li>
</ul>
<div class="note">Bailey &amp; Love Ch.4 | PROPPR Trial | CRASH-2</div>
<hr>

<div class="question"><span class="qnum">Q51. </span><span class="qtitle">Applications of Platelet-Rich Plasma (PRP) in Surgical Practice (2021)</span></div>
<div class="h3">Preparation:</div>
<ul>
<li>Autologous blood centrifuged &rarr; platelet conc 5&ndash;10&times; baseline (&gt; 1 million/&micro;L)</li>
</ul>
<div class="h3">Growth Factors in PRP:</div>
<ul>
<li>PDGF, TGF-&beta;, VEGF, EGF, IGF &rarr; stimulate healing, angiogenesis, collagen synthesis</li>
</ul>
<div class="h3">Surgical Applications:</div>
<ul>
<li><strong>Orthopaedics:</strong> cartilage repair, tendinopathy, bone graft</li>
<li><strong>Plastic surgery:</strong> wound healing, scar management, skin graft take</li>
<li><strong>Maxillofacial:</strong> dental implants, jaw reconstruction</li>
<li><strong>Colorectal:</strong> perianal fistula treatment</li>
<li><strong>Cardiothoracic:</strong> sternal wound healing post-sternotomy</li>
</ul>
<div class="h3">Evidence:</div>
<ul>
<li>Good evidence for knee osteoarthritis and chronic wounds</li>
<li>Evolving evidence for most other applications (Level IIb&ndash;III)</li>
</ul>
<div class="note">Bailey &amp; Love Ch.4</div>
<hr>

<div class="question"><span class="qnum">Q52. </span><span class="qtitle">Complications of Blood Transfusion</span></div>
<div class="h3">Mnemonic &mdash; INCH (Immune / Infective / Non-immune / Chemical):</div>
<ul>
<li><strong>Immune:</strong> haemolytic (ABO/minor Ag), FNHTR, urticaria, anaphylaxis, TRALI, TA-GvHD, alloimmunisation</li>
<li><strong>Infective:</strong> HIV (1:2.5M), Hep C (1:1.5M), Hep B (1:220,000), CMV, malaria, vCJD, bacterial contamination</li>
<li><strong>Non-immune:</strong> TACO, air embolism, hypothermia, dilutional coagulopathy</li>
<li><strong>Chemical/Metabolic:</strong> hyperkalaemia, hypocalcaemia, iron overload (&gt; 20 units)</li>
</ul>
<div class="h3">Most Dangerous &mdash; Acute Haemolytic Reaction (ABO mismatch):</div>
<ul>
<li>Intravascular haemolysis &rarr; DIC &rarr; ARF &rarr; death</li>
<li>First sign: &quot;feeling of impending doom&quot; / loin pain / haemoglobinuria</li>
<li><strong>Action: STOP transfusion immediately</strong>, maintain IV access, send unit + patient sample to lab</li>
</ul>
<div class="note">Bailey &amp; Love Ch.4</div>
<hr>

<div class="question"><span class="qnum">Q53. </span><span class="qtitle">Blood Products, Plasma Expanders for Polytrauma Shock; Complications of Transfusion</span></div>
<div class="h3">Blood Products:</div>
<p class="body">See Q45 (components) and Q48 (complications).</p>
<div class="h3">Crystalloids:</div>
<ul>
<li><strong>Hartmann's/Ringer's lactate</strong> &mdash; balanced, preferred in trauma (avoid hyperchloraemic acidosis)</li>
<li>Normal saline (0.9%) &mdash; risk of hyperchloraemic acidosis with large volumes</li>
<li>Dextrose &mdash; NOT for resuscitation (hypotonic, worsens cerebral oedema)</li>
</ul>
<div class="h3">Colloids:</div>
<ul>
<li>Human albumin solution (HAS 4&ndash;5%): liver failure, SBP treatment</li>
<li>Gelatin (Gelofusine): half-life 2&ndash;3h, risk of anaphylaxis</li>
<li><strong>Avoid HES (Voluven) in sepsis/renal impairment</strong> (CHEST trial: &uarr; mortality + AKI)</li>
</ul>
<div class="h3">Principles for Polytrauma:</div>
<ul>
<li>Permissive hypotension (MAP 50&ndash;65) until surgical haemostasis</li>
<li>1:1:1 haemostatic resuscitation, TXA early, Calcium, warm fluids</li>
<li>Minimal crystalloid to avoid dilutional coagulopathy</li>
</ul>
<div class="note">Bailey &amp; Love Ch.2 &amp; Ch.4 | ATLS 10th Ed</div>
<hr>

<div class="question"><span class="qnum">Q54. </span><span class="qtitle">TRALI &mdash; Definition, Mechanism and Management (2021)</span></div>
<div class="h3">Definition:</div>
<p class="body">New acute lung injury <strong>within 6 hours of transfusion</strong>, with PaO&sub2;/FiO&sub2; &lt; 300 mmHg, bilateral pulmonary infiltrates on CXR, NO evidence of pre-existing ALI or circulatory overload (TACO).</p>
<div class="h3">Mechanism (Two-Hit Model):</div>
<ul>
<li><strong>Hit 1:</strong> Patient&rsquo;s condition primes pulmonary neutrophils (surgery, sepsis, trauma)</li>
<li><strong>Hit 2:</strong> Donor anti-HLA (class I/II) or anti-HNA antibodies activate primed neutrophils</li>
<li>Neutrophil activation &rarr; ROS + proteases &rarr; endothelial damage &rarr; capillary leak &rarr; non-cardiogenic pulmonary oedema</li>
<li>Most implicated: FFP and platelets from multiparous female donors</li>
</ul>
<div class="h3">TRALI vs TACO:</div>
<table>
<tr><th>Feature</th><th>TRALI</th><th>TACO</th></tr>
<tr><td>Mechanism</td><td>Non-cardiogenic (Ab-mediated)</td><td>Cardiogenic (volume overload)</td></tr>
<tr><td>JVP/CVP</td><td>Normal/&darr;</td><td>Elevated</td></tr>
<tr><td>Response to diuretics</td><td>No</td><td>Yes</td></tr>
<tr><td>BNP/pro-BNP</td><td>Normal</td><td>Elevated</td></tr>
<tr><td>CXR</td><td>Bilateral infiltrates (no effusion)</td><td>Bilateral infiltrates + effusion</td></tr>
</table>
<div class="h3">Management:</div>
<ul>
<li><strong>STOP transfusion immediately</strong></li>
<li>High-flow O&sub2;; escalate to CPAP/BiPAP or mechanical ventilation</li>
<li>Lung-protective ventilation (6 mL/kg tidal volume + PEEP)</li>
<li><strong>NO diuretics</strong> (not volume overload)</li>
<li>Report to blood bank and haemovigilance (SHOT in UK)</li>
<li>Prevention: male-only or nulliparous donors for plasma-rich products</li>
</ul>
<div class="note">Bailey &amp; Love Ch.4 | SHOT Report 2023</div>
<hr>

<!-- ===== SECTION D ===== -->
<div class="section-header">SECTION D &mdash; ANAESTHESIA &amp; CRITICAL CARE &nbsp;(Q55&ndash;61)</div>

<div class="question"><span class="qnum">Q55. </span><span class="qtitle">Pharmacological Advances in Local Anaesthetics in Surgical Practice (2015)</span></div>
<div class="h3">Mechanism of Action:</div>
<p class="body">Reversibly block voltage-gated Na&plus; channels &rarr; prevent action potential propagation. Block order: autonomic &gt; sensory (pain, temp, touch) &gt; motor.</p>
<div class="h3">Common Local Anaesthetics:</div>
<table>
<tr><th>Agent</th><th>Type</th><th>Max Dose</th><th>Duration</th><th>Uses</th></tr>
<tr><td>Lidocaine</td><td>Amide</td><td>3 mg/kg (7 with adrenaline)</td><td>1&ndash;2h</td><td>Infiltration, IVRA, topical</td></tr>
<tr><td><strong>Bupivacaine</strong></td><td>Amide</td><td>2 mg/kg</td><td>4&ndash;8h</td><td>Spinal, epidural, PNB</td></tr>
<tr><td>Levobupivacaine</td><td>Amide</td><td>2.5 mg/kg</td><td>4&ndash;8h</td><td>Safer cardiac profile</td></tr>
<tr><td><strong>Ropivacaine</strong></td><td>Amide</td><td>3 mg/kg</td><td>4&ndash;6h</td><td>Epidural, less motor block</td></tr>
<tr><td>Prilocaine</td><td>Amide</td><td>6 mg/kg</td><td>2&ndash;3h</td><td>Bier&rsquo;s block, lower toxicity</td></tr>
<tr><td>Cocaine</td><td>Ester</td><td>1.5 mg/kg (topical only)</td><td>1h</td><td>ENT topical (vasoconstriction)</td></tr>
</table>
<div class="h3">Advances:</div>
<ul>
<li><strong>Liposomal bupivacaine (Exparel):</strong> sustained release up to 72h</li>
<li><strong>Ultrasound-guided blocks:</strong> greater accuracy, fewer complications</li>
<li><strong>Continuous peripheral nerve block catheters:</strong> improved post-op analgesia</li>
<li><strong>Adjuvants:</strong> dexamethasone (prolongs block 4&ndash;8h), dexmedetomidine, clonidine</li>
<li><strong>EMLA cream:</strong> lidocaine 2.5% + prilocaine 2.5% for venepuncture analgesia</li>
</ul>
<div class="h3">LAST (Local Anaesthetic Systemic Toxicity):</div>
<ul>
<li>CNS: perioral tingling &rarr; tinnitus &rarr; seizures &rarr; coma</li>
<li>Cardiac: arrhythmias, cardiac arrest (bupivacaine worst)</li>
<li>Treatment: STOP, 100% O&sub2;, <strong>20% Intralipid 1.5 mL/kg IV bolus</strong></li>
</ul>
<div class="note">Bailey &amp; Love Ch.14</div>
<hr>

<div class="question"><span class="qnum">Q56. </span><span class="qtitle">Regional Anaesthesia (2006)</span></div>
<div class="h3">Definition:</div>
<p class="body">Interruption of nerve conduction over a region using local anaesthetics, without loss of consciousness.</p>
<div class="h3">Types:</div>
<ul>
<li><strong>Central neuraxial:</strong> Spinal (subarachnoid), Epidural, Caudal</li>
<li><strong>Peripheral nerve blocks:</strong> Brachial plexus, femoral, sciatic, ankle block</li>
<li><strong>Intravenous regional (Bier&rsquo;s block):</strong> upper limb surgery</li>
<li>Plexus blocks, field blocks, wound infiltration</li>
</ul>
<div class="h3">Spinal vs. Epidural:</div>
<table>
<tr><th>Feature</th><th>Spinal</th><th>Epidural</th></tr>
<tr><td>Space</td><td>Subarachnoid (CSF)</td><td>Epidural space</td></tr>
<tr><td>Drug volume</td><td>Small (2&ndash;4 mL)</td><td>Large (10&ndash;20 mL)</td></tr>
<tr><td>Onset</td><td>Fast (2&ndash;5 min)</td><td>Slow (15&ndash;20 min)</td></tr>
<tr><td>Duration</td><td>Fixed (2&ndash;4h)</td><td>Continuous (catheter)</td></tr>
<tr><td>Level</td><td>L2/3 or L3/4</td><td>Any spinal level</td></tr>
<tr><td>Dural puncture</td><td>Yes (intentional)</td><td>Accidental = PDPH</td></tr>
<tr><td>Uses</td><td>Lower limb, perineal, abdominal</td><td>Labour, post-op analgesia</td></tr>
</table>
<div class="h3">Advantages of Regional over General Anaesthesia:</div>
<ul>
<li>Avoids airway instrumentation and GA risks</li>
<li>Better post-op analgesia, &darr; opioid use, &darr; PONV</li>
<li>Earlier mobilisation, shorter hospital stay</li>
<li>Reduced surgical stress response</li>
<li>Preferred in high-risk (cardiac/respiratory) patients</li>
</ul>
<div class="note">Bailey &amp; Love Ch.14</div>
<hr>

<div class="question"><span class="qnum">Q57. </span><span class="qtitle">Short Note on Epidural Anaesthesia</span></div>
<div class="h3">Anatomy:</div>
<ul>
<li>Space between ligamentum flavum and dura mater (fat, epidural veins, lymphatics)</li>
<li>Extends from foramen magnum to sacral hiatus</li>
</ul>
<div class="h3">Technique:</div>
<ul>
<li>Patient: sitting or lateral decubitus</li>
<li>Needle: Tuohy 16&ndash;18G, bevel upward</li>
<li>Identification: <strong>loss of resistance</strong> to saline technique</li>
<li>Catheter: 3&ndash;4 cm into epidural space</li>
<li>Test dose: 3 mL lignocaine 2% + adrenaline (detect intrathecal/intravascular)</li>
</ul>
<div class="h3">Drugs Used:</div>
<ul>
<li>Bupivacaine 0.1&ndash;0.5% &plusmn; fentanyl/morphine</li>
<li>Low concentration = sensory block (labour) | High = motor + sensory (surgery)</li>
</ul>
<div class="h3">Complications:</div>
<ul>
<li><strong>PDPH</strong> (dural puncture headache): postural, Rx = bed rest, caffeine, blood patch</li>
<li><strong>High spinal block:</strong> hypotension, bradycardia, respiratory arrest</li>
<li>Hypotension: IV fluids + ephedrine 6 mg IV</li>
<li>Epidural haematoma: back pain &rarr; paraplegia &rarr; emergency MRI + decompression</li>
<li>Epidural abscess: fever + neuro deficit &rarr; MRI + IV antibiotics &plusmn; drainage</li>
</ul>
<div class="h3">Uses:</div>
<p class="body">Labour analgesia | Major abdominal/thoracic/lower limb surgery | PCE (patient-controlled epidural)</p>
<div class="note">Bailey &amp; Love Ch.14</div>
<hr>

<div class="question"><span class="qnum">Q58. </span><span class="qtitle">Incentive Spirometry (2008)</span></div>
<div class="h3">Definition:</div>
<p class="body">A respiratory therapy device that encourages slow, deep, sustained inspiratory efforts to prevent/treat atelectasis by providing visual feedback of inspired volume.</p>
<div class="h3">Mechanism:</div>
<ul>
<li>Diaphragmatic breathing &rarr; opens collapsed alveoli &rarr; &uarr; FRC</li>
<li>Sustains flow-volume loop &rarr; recruits atelectatic segments</li>
</ul>
<div class="h3">Types:</div>
<ul>
<li><strong>Volume-oriented (preferred):</strong> measures inspired volume (e.g. Voldyne), target &gt; 2500 mL</li>
<li>Flow-oriented: visual balls indicating flow rate</li>
</ul>
<div class="h3">Indications:</div>
<ul>
<li>Post-operative (especially upper abdominal/thoracic surgery)</li>
<li>COPD, pneumonia, neuromuscular disease, atelectasis</li>
<li>Pre-op conditioning in high-risk patients</li>
</ul>
<div class="h3">Technique:</div>
<ul>
<li>Sit upright | Exhale normally | Seal lips on mouthpiece</li>
<li>Inhale slowly and deeply | Hold 5&ndash;10 seconds | 10 breaths/hour while awake</li>
</ul>
<div class="h3">Benefits:</div>
<ul>
<li>&darr; Post-op pulmonary complications (pneumonia, atelectasis)</li>
<li>Improves FVC, FEV&sub1;, SpO&sub2;</li>
</ul>
<div class="note">Bailey &amp; Love Ch.14 | Cochrane Review</div>
<hr>

<div class="question"><span class="qnum">Q59. </span><span class="qtitle">Management of Cardiac Arrest During Surgery (2023)</span></div>
<div class="h3">Reversible Causes &mdash; 4Hs and 4Ts:</div>
<ul>
<li><strong>4H:</strong> Hypoxia | Hypovolaemia | Hypo/Hyperkalaemia | Hypothermia</li>
<li><strong>4T:</strong> Tension pneumothorax | Tamponade | Thrombosis (PE/MI) | Toxins</li>
</ul>
<div class="h3">Surgical-Specific Causes:</div>
<ul>
<li>Massive haemorrhage | Vagal reactions | Air embolism</li>
<li>Malignant hyperthermia (MH) | LAST (local anaesthetic toxicity)</li>
<li>Cement implantation syndrome | Positioning issues</li>
</ul>
<div class="h3">Immediate Management (ALS Algorithm):</div>
<ul>
<li>1. Recognise arrest: unresponsive, no pulse, no normal breathing</li>
<li>2. Call for help / crash team</li>
<li>3. CPR: 30:2, hard and fast (100&ndash;120 bpm, 5&ndash;6 cm depth)</li>
<li>4. Intubate early (anaesthetist usually present)</li>
<li>5. Adrenaline 1 mg IV every 3&ndash;5 min</li>
<li>6. <strong>Shockable (VF/pVT):</strong> defibrillate 200J biphasic immediately</li>
<li>7. Amiodarone 300 mg IV after 3rd shock for VF/pVT</li>
<li>8. <strong>Non-shockable (PEA/Asystole):</strong> CPR + adrenaline + treat reversible causes</li>
</ul>
<div class="h3">Special Situations:</div>
<ul>
<li><strong>Malignant Hyperthermia:</strong> STOP trigger agent, <strong>Dantrolene 2.5 mg/kg IV</strong>, active cooling</li>
<li><strong>LAST:</strong> 20% Intralipid 1.5 mL/kg IV bolus</li>
<li><strong>Tension pneumothorax:</strong> needle decompression 2nd ICS MCL &rarr; chest drain</li>
<li><strong>Air embolism:</strong> left lateral Trendelenburg, aspirate via CVP, 100% O&sub2;</li>
</ul>
<div class="note">Bailey &amp; Love Ch.14 | ALS Guidelines 2021 (Resuscitation Council UK)</div>
<hr>

<div class="question"><span class="qnum">Q60. </span><span class="qtitle">Pain Relief in Surgery / Post-Operative Pain Management (2009, 2011)</span></div>
<div class="h3">WHO Analgesic Ladder (adapted for post-op):</div>
<ul>
<li><strong>Step 1 (Mild):</strong> Paracetamol 1g QDS + NSAIDs (ketorolac, ibuprofen, diclofenac)</li>
<li><strong>Step 2 (Moderate):</strong> Weak opioids &mdash; codeine, tramadol &plusmn; adjuvants</li>
<li><strong>Step 3 (Severe):</strong> Strong opioids &mdash; morphine, fentanyl, oxycodone</li>
</ul>
<div class="h3">Multimodal Analgesia (gold standard &mdash; reduces opioid use):</div>
<p class="body">Paracetamol + NSAID + Regional block + Opioid PRN</p>
<div class="h3">Key Analgesic Drugs:</div>
<table>
<tr><th>Drug</th><th>Mechanism</th><th>Dose</th><th>Notes</th></tr>
<tr><td>Paracetamol</td><td>Central COX inhibition</td><td>1g QDS PO/IV</td><td>Safe, start ASAP</td></tr>
<tr><td>NSAIDs</td><td>Peripheral COX-1/2 inhibition</td><td>Ketorolac 15&ndash;30 mg</td><td>Caution: renal, GI, bleeding</td></tr>
<tr><td><strong>Morphine</strong></td><td>&micro; opioid receptor agonist</td><td>0.1 mg/kg IV titrated</td><td>Gold standard severe pain</td></tr>
<tr><td>Fentanyl</td><td>&micro; agonist, rapid onset</td><td>1&ndash;2 mcg/kg IV</td><td>Patch for chronic pain</td></tr>
<tr><td>Gabapentin</td><td>Voltage-gated Ca&sup2;&plus; channel</td><td>300 mg TDS</td><td>Reduces opioid use</td></tr>
<tr><td>Ketamine</td><td>NMDA antagonist</td><td>0.1&ndash;0.5 mg/kg</td><td>Opioid-sparing</td></tr>
</table>
<div class="h3">Delivery Methods:</div>
<ul>
<li><strong>PCA</strong> (IV morphine): safe, patient autonomy, 5 min lockout</li>
<li><strong>Epidural (PCE):</strong> bupivacaine &plusmn; fentanyl &mdash; best for thoracic/abdominal surgery</li>
<li><strong>Peripheral nerve blocks:</strong> TAP (abdominal), femoral/sciatic (lower limb)</li>
</ul>
<div class="h3">ERAS Pain Principles:</div>
<ul>
<li>Pre-emptive analgesia (pre-op gabapentin/NSAID) | Minimal opioids | Early mobilisation</li>
</ul>
<div class="note">Bailey &amp; Love Ch.14</div>
<hr>

<div class="question"><span class="qnum">Q61. </span><span class="qtitle">Invasive and Non-Invasive Techniques of Post-Operative Analgesia (2021)</span></div>
<div class="h3">NON-INVASIVE TECHNIQUES:</div>
<ul>
<li><strong>Oral analgesics:</strong> paracetamol, NSAIDs, opioids, gabapentinoids, ketamine</li>
<li><strong>Transdermal patches:</strong> fentanyl (72h), buprenorphine &mdash; chronic/cancer pain</li>
<li><strong>Inhaled &mdash; Entonox:</strong> 50% N&sub2;O + 50% O&sub2; &mdash; labour, dressing changes</li>
<li><strong>TENS:</strong> gate control theory &mdash; mild to moderate pain</li>
<li><strong>Ice/cold therapy:</strong> local anti-inflammatory analgesia</li>
</ul>
<div class="h3">INVASIVE TECHNIQUES:</div>
<ul>
<li><strong>IV PCA:</strong> morphine 1 mg bolus, 5 min lockout, 24h ceiling dose</li>
<li><strong>Epidural (PCE):</strong> bupivacaine + fentanyl via catheter &mdash; gold standard for major surgery</li>
<li><strong>Spinal opioids:</strong> intrathecal morphine 0.1&ndash;0.3 mg at time of spinal &mdash; 12&ndash;24h analgesia</li>
<li><strong>Peripheral nerve blocks (single shot or catheter):</strong>
  <ul>
    <li>TAP block &mdash; abdominal surgery somatic pain</li>
    <li>Femoral nerve block &mdash; hip/knee surgery</li>
    <li>Sciatic nerve block &mdash; foot/ankle surgery</li>
    <li>Brachial plexus block &mdash; upper limb surgery</li>
    <li>Intercostal nerve block &mdash; rib fractures, thoracotomy</li>
    <li>Paravertebral block &mdash; mastectomy, thoracic surgery (unilateral)</li>
  </ul>
</li>
<li><strong>Continuous wound infusion catheters</strong></li>
<li><strong>Intra-articular injection:</strong> morphine/bupivacaine (knee arthroscopy)</li>
</ul>
<div class="h3">Monitoring Post-Op Analgesia:</div>
<ul>
<li>Pain score (NRS 0&ndash;10 or VAS) | Sedation score | Respiratory rate | PONV</li>
</ul>
<div class="note">Bailey &amp; Love Ch.14</div>
<hr>

<div style="text-align:center; color: var(--muted); font-size: 12px; margin: 20px 0 10px 0;">
  <strong>END OF DOCUMENT</strong><br>
  Bailey and Love&rsquo;s Short Practice of Surgery, 28th Edition &bull; MS General Surgery Exam Prep<br>
  Questions 37&ndash;61 | Chapters 2, 4, 14
</div>

<button class="print-btn" onclick="window.print()">📄 Save / Print as PDF</button>

</body>
</html>